Transcription and translation dual-regulated oncolytic herpes simplex virus vector

By recombining herpes simplex virus vectors, combining miRNA target sequences and immune stimulators, the problem of limited effectiveness of existing cancer treatment methods has been solved, significantly improving the killing ability of tumor cells and prolonging the survival of patients.

CN118922550APending Publication Date: 2024-11-08VIROGIN BIOTECH CANADA LTD +1
View PDF 16 Cites 0 Cited by

Patent Information

Application Number
CN202380019163.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-29
Filing Date
2023-01-30
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing cancer treatment methods, including immunotherapy, have limited effects, especially for patients with advanced tumors, and there is no effective treatment method, which leads to a shortening of patient survival and urgently requires new treatment methods.

Method used

Using recombinant herpes simplex virus as a vector, by modifying its genome, including miRNA target sequence and inactivated mutations, combined with immune stimulators and checkpoint blocking peptides, enhances the targeting and immune regulation ability of tumor cells, and forms a new cancer treatment methods.

Benefits of technology

It significantly improves the killing ability of tumor cells, extends the patient's survival, and provides new possibilities for treating cancer, especially for advanced tumor patients who have not been effective in traditional treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922550A_ABST
    Figure CN118922550A_ABST
Patent Text Reader

Abstract

An HSV vector has ICP 27 under the control of a CXCR4 promoter and ICP 34.5 under the control of miRNA-124 / 143, and the vector has a deletion of an RL region and an RS region of a viral genome. In a selected embodiment, the mutation is a deletion containing a second copy of the ICP34.5 gene. Such constructs can provide enhanced safety without sacrificing efficacy. The HSV vector also incorporates a cassette of cytokines encoding an expression virus of IL-12, IL-15 / IL-15RA under the control of a CMV promoter.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Incorporation by reference into the priority application

[0002] Any and all applications indicated as claiming foreign or domestic priority on the Application Information Sheet filed with the present application are incorporated herein by reference. Technical Field

[0003] The present invention generally relates to oncolytic herpes simplex virus (oHSV) vectors that express molecules that stimulate the immune system.

[0004] Reference to a sequence listing, table or computer program

[0005] The contents of the electronic sequence listing (VIRO_416PC_SeqList.text.Xml; size: 10.9 bytes; creation date: January 29, 2023) are incorporated herein by reference in their entirety. Background Art

[0006] Malignant tumors seriously threaten human life and health. Despite the existence of various standard treatment options, such as surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy (including immune checkpoint inhibitors), most patients with advanced tumors still have a poor prognosis. At present, tumor immunotherapy has made breakthrough progress in the treatment of tumors. Immune target drug therapy (such as immune checkpoint inhibition) and immune cell therapy (such as chimeric antigen receptor T-cell (CAR-T)) have caused changes in the field of anti-tumor therapy. However, in the currently approved indications of checkpoint inhibitors, the efficacy of a single drug is only about 30% (Jiang et al., 2020, Progress and Challenges in Precise Treatment of Tumors With PD-1 / PD-L1 Blockade. Frontiers in Immunology, 11 (March)); and CAR-T therapy mainly targets only cluster of differentiation 19 (CD19) and B cell maturation antigen (BCMA) highly expressed in B cell tumors. Clinical effectiveness in solid tumors remains to be confirmed (Long et al., 2018, CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success. Frontiers in Immunology, 9 (December), 2740). While there are clear long-term signs of the benefits of immunotherapy, there are still a variety of malignancies.

[0007] There is no effective treatment for malignant tumors that relapse after standard treatment and are difficult to treat with standard treatment. Therefore, patients in this situation may die faster due to extensive tumor metastasis or invasion of important organs. Therefore, the demand for effective treatment for such patients is largely unmet, resulting in an urgent need to develop new treatments to control disease progression and prolong patient survival.

[0008] The present invention overcomes the shortcomings of current cancer therapies, including immunotherapy, and further provides additional unexpected benefits.

[0009] For all the contents mentioned in the background section, just because they are mentioned in the background section, it does not necessarily constitute prior art, and it should not be assumed that they are prior art. Along this line of thought, unless it is clearly stated as prior art, the problems recognized in the prior art mentioned in the background section or related to such contents should not be considered as prior art. Instead, anything mentioned in the background section should be considered as part of the inventor's solution to a specific problem, which itself can also be inventive.

[0010] Summary of the invention

[0011] In short, the present invention relates to treating cancer and compositions and methods with recombinant herpes simplex virus vectors. In one embodiment of the present invention, a recombinant herpes simplex virus is provided, comprising a modified oncolytic herpes virus genome, wherein the modified herpes virus genome comprises at least one miRNA target sequence operably linked to a first copy of the ICP34.5 gene, and the second copy of the ICP34.5 gene comprises an inactivating mutation. In various embodiments, the recombinant virus may comprise one to ten miRNA target sequences operably linked to a first copy of the ICP34.5 gene.

[0012] In other embodiments, the miRNA target sequence can bind to at least two different miRNAs (e.g., one or more of miR-124, miR-124*, and miR-143). In certain embodiments, the miR target sequence includes SEQ ID NO.2 (miR-124 binding sequence); SEQ ID NO.3 (miR-143 binding sequence); SEQ ID NO.9 (miR-223 binding sequence); and SEQ ID NO.10 (miR-125b binding sequence). Other miRNA target sequences that can be used in other embodiments of the present invention include, for example, mlR-122, miR-127, miR-128, miR-129, miR-129*, miR-132, mlR-133a, mlR133b, miR-135b, miR-136, miR-136*, miR-137, miR-139-5p, mlR-145, miR-154, miR-184, miR-188, miR-204, mlR216a, miR-299, miR-300-3p, miR-300-5p, miR-323, miR-329, miR-337, miR-335, miR-34 1.miR-369-3p,miR-369-5p,miR-376a,miR-376a*,miR-376b-3p,miR-376b-5p,mi R-376c,miR-377,miR-379,miR-379*,miR-382,miR-382*,miR-409-5p,miR-410,m iR-411,miR-431,miR-433,miR-434,miR-451,miR-466b,miR-485,miR-495,miR-5 39. miR-541, miR-543*, miR-551b, miR-758 and miR-873, WO2020 / 113151 are incorporated herein by reference in their entirety.

[0013] In another embodiment, the recombinant herpes virus may further include at least one nucleic acid encoding non-viral protein. Examples of non-viral proteins include immunostimulatory factors, antibodies and checkpoint blocking peptides (e.g., derived from PD-1 or derived from PD-L1 or PD-L2 peptides, or antibodies for checkpoint inhibitors, such as anti-PD-1, anti-PD-L1, anti-PD-L2 or anti-CTLA-4), wherein at least one nucleic acid is operably connected to a strong promoter (e.g., viral promoter, such as CMV, or other promoters, such as EF-1α or CAG). Alternatively, the at least one nucleic acid is operably connected to a tumor-specific or tumor-associated promoter (e.g., CEA promoter, CXCR4 promoter, hTERT promoter, survivin promoter, BRMS1 promoter, MCM5 promoter or RAN promoter). In a particularly preferred embodiment, non-viral protein is one or all of IL12, IL15, IL15 receptor alpha subunits. Representative examples of such sequences include SEQ ID NO. 4 (IL12); SEQ ID NO. 5 (IL15); and SEQ ID NO. 6 (IL15 receptor alpha subunit).

[0014] In yet another embodiment, the recombinant herpes simplex virus further comprises a nucleic acid sequence encoding a glycoprotein with enhanced fusogenicity (compared to a similar wild-type virus). Examples include a variety of transgenes (e.g., fusion glycoproteins from Gibbon Ape Leukemia Virus (GALV)) and / or mutations that enhance HSV fusion, including, for example, truncations or mutations in glycoprotein B, glycoprotein K, and / or UL20.

[0015] In yet other embodiments, the recombinant herpes virus may further comprise an ICP27 promoter sequence operably linked to a first copy of an ICP47 gene, wherein the native promoter of the ICP47 gene comprises an inactivating deletion.

[0016] In yet other embodiments, the recombinant herpes virus may further comprise an inactivating mutation in at least one copy of the ICP4 gene.

[0017] In yet other embodiments, the recombinant herpes virus may further comprise a tumor-specific promoter operably linked to the first copy of the ICP27 gene, wherein the native ICP27 promoter comprises an inactivating mutation.

[0018] Also provided are therapeutic compositions comprising the recombinant herpes viruses described herein, as well as methods of lysing tumor cells and methods of treating cancer in an individual comprising the step of administering to the individual a recombinant herpes virus described herein.

[0019] This "Summary of the Invention" has been provided to introduce in a simplified form some concepts that are further described in detail in the following [Implementation Methods]. Unless otherwise explicitly stated, this "Summary of the Invention" is not intended to identify key features or essential features of the claimed content, nor is it intended to limit the scope of the claimed content.

[0020] The details of one or more embodiments are as follows. Features illustrated or described in conjunction with one exemplary embodiment may be combined with features of other embodiments. Therefore, any of the various embodiments described herein may be combined to provide more embodiments. If necessary, various aspects of the embodiments may be modified to adopt the concepts of the various patents, patent applications, and patent disclosures as indicated herein, thereby providing yet more embodiments. Other features, objects, and advantages will be apparent from the specification, drawings, and claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] The exemplary features of the present invention, its nature and various advantages will be apparent from the accompanying drawings and the following detailed description of various embodiments. Non-limiting and non-exhaustive embodiments are described with reference to the accompanying drawings, wherein similar labels or reference numerals refer to similar parts in the various views unless otherwise specified. The sizes and relative positions of components in the drawings are not necessarily drawn to scale. For example, the shapes of various components are selected, enlarged and positioned to improve the clarity of the drawings. The components drawn are selected in specific shapes for easy identification in the drawings. One or more embodiments are described below with reference to the accompanying drawings, wherein:

[0023] Figure 1 The Transcription and Translation Dual Regulated (TTDR) system as exemplified by the overall structural organization of the double-stranded deoxyribonucleic acid (DNA) elements of VG2062 (also known as VG203) is schematically depicted.

[0024] Figure 2 Graphs (top) and tables (bottom) showing microRNA-mediated control of viral gene expression.

[0025] Figure 3 Comparison of cell-cell fusion phenotypes among three recombinant oncolytic HSV.

[0026] Figure 4 Depicted are qPCR-based quantification of VG2062 ICP27 DNA and host cell CXCR4 mRNA in nine different urological tumor cell lines.

[0027] Figure 5Depicted are the replication kinetics of VG2062 on a panel of nine different urological tumor cell lines.

[0028] Figure 6 Depicted are the IC50 cytotoxicity values ​​(measured as MOI) of VG2062 and VG161 on a panel of 10 different urological tumor cell lines.

[0029] Figure 7 Depicted are ELISA-based quantification of human IL-12 and human IL-15 loads secreted by VG2062 and VG161 following infection of a panel of 10 different urological tumor cell lines.

[0030] Figure 8 Depicted are tumor volumes from immunocompromised mice bearing A549 tumors treated with three dose injections of VG2062.

[0031] Fig. 9 Depicted are tumor volumes from immunocompromised mice bearing PC3 tumors treated with increasing single doses of VG2062.

[0032] Fig.10 Depicted are tumor volumes of immunocompromised mice bearing DU145 tumors treated with increasing single doses of VG2062.

[0033] Fig.11 Depicted are tumor volumes from immunocompromised mice bearing UM-UC-3 tumors treated with a single injection of low or high doses of VG2062.

[0034] Fig.12 Depicted are tumor volumes from immunocompromised mice bearing BT-474 tumors treated with a single injection of low or high doses of VG2062.

[0035] Fig.13 Depicted are tumor volumes from immunocompetent mice bearing EMT-6 tumors treated with three injections of mVG2031 at low or high doses.

[0036] Fig.14 Depicted are tumor volumes from immunocompetent mice bearing EMT-6 tumors treated with mVG2031, with anti-PD-1 antibody, or with a combination of both mVG2031 and anti-PD-1 antibody.

[0037] Fig.15 Depicted are tumor volumes from immunocompetent mice bearing Renca tumors treated with a low-dose single injection of mVG2031, a high-dose single injection of mVG2031, low-dose three injections of mVG2031, or high-dose three injections of mVG2031.

[0038] Fig.16A and Fig. 16B Depicted from the left ( Fig. 16B ) and right side ( Fig.16A ) Tumor volume in immunocompetent mice implanted with Renca tumors on both flanks and treated with mVG2031, with anti-PD-1 antibody, or with a combination of mVG2031 and anti-PD-1 antibody.

[0039] Fig.17 Depicted are tumor volumes from immunocompromised mice bearing A-498 tumors treated with a single injection of low or high doses of VG2062.

[0040] Fig.18 Depicted are mouse eyes after corneal scarification and inoculation with wild-type HSV-1 strain 17+ or low or high doses of VG2062. DETAILED DESCRIPTION

[0041] The term "oncolytic herpes virus" or "oHSV" generally refers to a herpes virus that can replicate in tumor cells and kill tumor cells. In certain embodiments, the virus can be modified to target tumor cells with higher selectivity. Representative examples of oncolytic herpes viruses are described in U.S. Patent Nos. 7,223,593, 7,537,924, 7,063,835, 7,063,851, 7,118,755, 8,216,564, 8,277,818, and 8,680,068, which are incorporated herein by reference in their entirety.

[0042] As used herein, "treatment" means a method of obtaining a beneficial or desired result (including a clinical result). A beneficial or desired clinical result may include, but is not limited to, relief or alleviation of one or more detectable or undetectable symptoms or conditions, reduction in the extent of the disease, a stable (i.e., non-worsening) disease state, prevention of disease spread, delay or slowing of disease progression, alleviation or alleviation of the disease state, reduction of disease recurrence, and (partial or complete) improvement. The term "treatment" may also mean prolonging survival compared to the expected survival without treatment.

[0043] Representative forms of cancer include carcinomas, leukemias, lymphomas, myelomas, and sarcomas. Further examples include, but are not limited to, cancers of the bile duct, brain (e.g., glioblastoma), breast, cervix, colorectum, CNS (e.g., acoustic neuroma, astrocytoma, craniopharyngioma, ependymoma, glioblastoma, hemangioblastoma, medulloblastoma, meningioma, neuroblastoma, oligodendroglioma, pinealoma, and retinoblastoma), endometrial lining, hematopoietic cells (e.g., leukemia and lymphoma), kidney, larynx, lung, liver, oral cavity, ovary, pancreas, prostate, skin (e.g., melanoma and squamous cell carcinoma), and thyroid. Cancer may include solid tumors (e.g., sarcomas, such as fibrosarcomas, myxosarcoma, liposarcoma, chondrosarcoma, and osteogenic sarcomas), diffuse (e.g., leukemia), or some combination of the above (e.g., metastatic cancers with solid tumors and disseminated or diffuse cancer cells). Cancer may also be resistant to traditional treatments, such as traditional chemotherapy and / or radiation therapy.

[0044] Particularly preferred cancers to be treated include lung tumors, breast and prostate tumors, glioblastomas, urinary tumors, tumors of the gastrointestinal tract (and related organs) (e.g., esophagus), bile duct carcinomas, anus, stomach, bladder, kidney, intestine, pancreas, colon and liver, and all surface injectable tumors (e.g., melanoma). Benign tumors and other conditions with undesirable cell proliferation can also be treated. More preferably, the cancer to be treated expresses a detectable amount of CXC motif chemokine receptor 4 (CXCR4).

[0045] To further understand the various embodiments herein, the following sections describing the various embodiments are provided: A. Oncolytic herpes virus; B. Specific herpes virus construct - VG2062; C. Post-transcriptional regulation; D. ICP27 expression in VG2062 is transcriptionally controlled; E. Enhanced expression of cargo in VG2062; F. Truncated glycoprotein B; G. Modified ICP47 promoter; H. Therapeutic composition; and I. Administration.

[0046] A. Oncolytic herpes virus

[0047] Herpes simplex virus (HSV) 1 and 2 are members of the herpesviridae family that infect humans. The HSV genome contains two unique segments, which are called unique long (U L ) and unique short (U S ) region. Each of these segments is flanked by a pair of identical inverted repeat sequences, wherein the flanking U L R L , and the side is connected to U SR S . There are approximately 75 known open reading frames. The viral genome has been modified to develop oncolytic viruses for use, for example, in cancer therapy. Tumor-selective replication of HSV can be conferred by mutations in the HSV ICP34.5 (also known as γ34.5) gene. HSV contains two copies of ICP34.5. Mutations that inactivate one or both copies of the ICP34.5 gene are known to be non-neurotoxic, i.e., non-toxic / non-neurotoxic and oncolytic. Tumor-selective replication of HSV can also be conferred by controlling the expression of key viral genes such as ICP27 and / or ICP4.

[0048] Suitable oncolytic HSV can be derived from HSV-1 or HSV-2, including any laboratory strain or clinical isolate. In some embodiments, oHSV can be derived from one of the laboratory strains HSV-1 strain 17, HSV-1 strain F, or HSV-2 strain HG52. In other embodiments, it can be derived from non-laboratory strain JS-1. Other suitable HSV-1 viruses include HrrR3 (Goldstein and Weller, J. Virol. 62, 196-205, 1988), G2O7 (Mineta et al. Nature Medicine. 1(9):938-943, 1995; Kooby et al. The FASEB Journal, 13(11):1325-1334, 1999); G47Delta (Todo et al. Proceedings of the National Academy of Sciences. 2001; 98(11):6396-6401); HSV 1716 (Mace et al. Head & Neck, 2008; 30(8):1045-1051; Harrow et al. Gene Therapy. 2004; 11(22):1648-1658); HF10 (Nakao et al. Cancer Research. 2006; 11(23):1648-1658); Gene Therapy. 2011; 18(3): 167-175); NV1020 (Fong et al. Molecular Therapy, 2009; 17(2): 389-394); T-VEC (Andtbacka et al. Journal of Clinical Oncology, 2015: 33(25): 2780-8); J100 (Gaston et al. PloS one, 2013; 8(11): e81768); M002 (Parker et al. Proceedings of the National Academy of Sciences, 2000; 97(5): 2208-2213); NV1042 (Passer et al. Cancer Gene Therapy. 2013; 20(1): 17-24); G2O7-IL2 (Carew et al. Molecular Therapy, 2001; 4(3): 250-256); rQNestin34.5 (Kambara et al. Cancer Research, 2005; 65(7):2832-2839); G47Δ-mIL-18 (Fukuhara et al. Cancer Research, 2005; 65(23):10663-10668); and vectors disclosed in PCT application PCT / US2017 / 030308 entitled “HSV Vectors with Enhanced Replication in Cancer Cells” and PCT application PCT / US2017 / 018539 entitled “Compositions and Methods of Using Stat1 / 3 Inhibitors with Oncolytic Herpes Virus”, all of which are incorporated herein by reference in their entirety. .

[0049] The oHSV vector has at least one γ34.5 gene modified with a miRNA target sequence in the 3'UTR as disclosed herein; there is no unmodified γ34.5 gene in the vector. In some embodiments, the oHSV has two modified γ34.5 genes; in other embodiments, the oHSV has only one γ34.5 gene, and it is modified. In some embodiments, the modified γ34.5 gene is constructed in vitro and inserted into the oHSV vector as a replacement of a viral gene. When the modified γ34.5 gene is a replacement of only one γ34.5 gene, the other γ34.5 is deleted. Any of the native γ34.5 genes may be deleted. In one embodiment, the terminal repeat region comprising the γ34.5 gene and the ICP4 gene is deleted. As discussed herein, the modified γ34.5 gene may include additional changes, such as having an exogenous promoter.

[0050] oHSV may have additional mutations, which may include disabling mutations (e.g., deletions, substitutions, insertions) that may affect the toxicity of the virus or its ability to replicate. For example, mutations may occur in any one or more of ICP6, ICPO, ICP4, ICP27, ICP47, ICP24, ICP56. Preferably, a mutation occurring in one of these genes (optionally, in both copies of the gene where appropriate) causes HSV to be unable to express the corresponding functional polypeptide (or to have reduced expression capacity). In some embodiments, the promoter of the viral gene may be replaced by a promoter that is selectively active in the target cell, or is inducible after delivery of an inducing agent, or is inducible after a cellular event or under a specific environment.

[0051] oHSV may have additional mutations, which may include disabling mutations (e.g., deletions, substitutions, insertions) that may reduce the risk of recombination events in non-unique segments of the viral genome duplication. For example, mutations may occur in R S Area, R L In some embodiments, the promoter of a viral gene can be replaced by a promoter of a different viral gene that reduces the risk of recombination events in non-unique segments of native or natural promoter repeats.

[0052] In certain embodiments, the expression of ICP4 or ICP27 is controlled by an exogenous promoter (e.g., a tumor-specific promoter). Exemplary tumor-specific promoters include survivin, CEA, CXCR4, PSA, ARR2PB, hTERT, RAN, BRMS1, MCM5, or telomerase; other suitable tumor-specific promoters may be specific to a single tumor type and are known in the art. Other elements may be present. In some cases, enhancers are present, such as NFkB / oct4 / sox2 enhancers. Similarly, the 5'UTR may be exogenous, such as a 5'UTR from a growth factor gene (e.g., FGF). For exemplary constructs, see Figure 1 The representative sequence of CXCR4 promoter is also shown in SEQ ID NO.8.

[0053] oHSV may also have genes and nucleotide sequences of non-HSV origin. For example, the oHSV genome may contain sequences encoding prodrugs, sequences encoding cytokines or other immunostimulatory factors, tumor-specific promoters, inducible promoters, enhancers, sequences homologous to host cells, etc. Exemplary sequences encode IL12, IL15, IL15 receptor α subunit, OX40L, CTLA-4 blockers, PD-L1 blockers or PD-1 blockers. For sequences encoding products, they are operably linked to promoter sequences and other regulatory sequences necessary or required for expression (e.g., enhancers, polyadenylation signal sequences).

[0054] In certain embodiments of the invention, the oHSV expresses a PD-1 blocker, a PD-L1 blocker, or a PD-L2 blocker, such as a protein or peptide sequence that blocks, binds to, or otherwise inhibits PD-1, PD-L1, PD-L2, or a ligand thereof when expressed. Briefly, PD-1 (or "programmed cell death protein 1", also known as CD279) is a protein on the surface of T cells and B cells that acts to downregulate the immune system, thereby curbing T cell inflammatory activity and preventing or reducing the ability of the immune system to kill tumor cells.

[0055] PD-1 has two ligands: PD-L1 and PD-L2. Representative examples of PD-1, PD-L1, and PD-L2 antagonists include peptides and antibodies that statistically significantly block, bind to, or otherwise inhibit the binding of PD-1 or its ligands, thereby inhibiting or reducing their activity. Representative examples of PD-L1 antagonists include nucleic acid sequences encoding any of the following: Atezolizumab (TECENTRIQ - a humanized anti-PD-L1 antibody); Avelumab (BAVENCIO - a fully human anti-PD-L1 antibody); Durvalumab (IMFINZI - a human anti-PD-L1 antibody); Durvalumab (IMFINZI - a fully human IgG1 antibody); KN035; Cosibelimab (CK-301, from Checkpoint Therapeutics); AUNP12 (a peptide PD-1 / PD-L1 inhibitor from Aurigene and Laboratoires Pierre Fabre); CA-170; and BMC-986189 (a macrocyclic peptide).

[0056] Representative examples of PD-1 antagonists include nucleic acid sequences encoding any of the following representative anti-PD-1 antibodies: Nivolumab (OPDIVO - a human anti-PD-1 antibody); Pembrolizumab (KEYTRUDA - a humanized anti-PD-1 antibody); Cemiplimab (LIBTAYO - an anti-PD-1 antibody); Dostarlimab (JEMPERLI - an anti-PD-1 antibody); Vopratelimab (JTX-4014), from Jounce Therapeutics; Spartalizumab (PDR001), from Novartis; Camrelizumab (SHR1210) - an anti-PD-1 monoclonal antibody, from Jiangsu Hengrui Medicine Co., Ltd.; Sintilimab (IBI308), a human anti-PD-1 antibody developed by Innovent and Eli Lilly; Tislelizumab (BGB-A317 - a humanized IgG4 anti-PD-1 monoclonal antibody; Toripalimab (JS 001), a humanized IgG4 anti-PD-1 monoclonal antibody; INCMGA00012 (MGA012), a humanized IgG4 monoclonal antibody developed by Incyte and MacroGenics; AMP-224, from AstraZeneca / Medlmmune and GlaxoSmithKline; and AMP-514 (MEDI0680), from AstraZeneca.

[0057] Representative patents and patent applications describing PD-1, PD-L1 and PD-L2 antagonists, methods for evaluating their activity, and nucleic acid sequences encoding the same include, for example: U.S. Patent Nos. 7,595,048, 7,943,743, 8,952,136, 8,217,149, 8,609,089, 8,735,553, 8,779,105, 8,779,108, 8993731 and 9,815,897; U.S. Publication No. 2010 / 02 03056, 2010 / 0266617, 2011 / 0229461, 2013 / 0017199, 2014 / 341917, 2015 / 0203579, 2016 / 0311903, 2016 / 0376367, 2016 / 0311903, 2017 / 0044259 and 2018 / 0346569; and PCT Publication No. WO2012145493; all of the above patents are incorporated herein by reference in their entirety.

[0058] In certain embodiments of the invention, the oHSV expresses a nucleic acid sequence encoding a CTLA-4 antagonist. In short, CTLA-4 also has two major ligands: CD80 and CD86 on the surface of T cells. Representative examples of CTLA-4 antagonists include peptides and antibodies that statistically significantly block, bind to, or otherwise inhibit the binding of CTLA-4 or its ligands, thereby inhibiting or reducing its activity. Representative examples of CTLA-4 antagonists include: Ipilimumab (Yervoy-a fully human anti-CTLA-4 monoclonal antibody, IgG1 isotype); and Tremelimumab (Imjudo-a fully human anti-CTLA-4 antibody, IgG2 isotype). Representative examples of patents involving nucleic acid sequences encoding anti-CTLA-4 antibodies and variants thereof include U.S. Pat. Nos. 5,811,097, 5,855,887, 5,977,318, 6,051,227, 6,207,156, 6,682,736, 6,984,720, 7,109,003, 7,132,281, and 10,196,445, and PCT Publication Nos. WO 2001 / 014424, WO 2004 / 035607, and WO 2005 / 0201994, all of which are incorporated herein by reference in their entirety.

[0059] The regulatory region of the viral gene can be modified to include a response element that affects expression. Exemplary response elements include response elements of NF-κB, Oct-3 / 4-SOX2, enhancers, silencers, cAMP response elements, CAAT enhancer binding sequences and insulators. Other response elements may also be included. The viral promoter can be replaced with different promoters. The selection of the promoter will depend on a variety of factors, such as the use of the proposed HSV vector, the treatment of the patient, the disease state or condition and the ease of applying the inducer (for inducible promoters). For the treatment of cancer, when the promoter is usually replaced, it will be replaced with a cell-specific or tissue-specific or tumor-specific promoter. Tumor-specific, cell-specific and tissue-specific promoters are known in the art. Other gene elements may also be modified. For example, the 5'UTR of the viral gene can be replaced with an exogenous UTR.

[0060] B. Specific herpes virus construct – VG2062

[0061] Figure 1 A preferred construct of the present invention is provided. In brief, Figure 1The overall structural organization of the double-stranded deoxyribonucleic acid (DNA) elements of VG2062 is schematically depicted. "CXCR4" means CXC motif chemokine receptor 4; "CMV" means cytomegalovirus; "gB" means glycoprotein B; "ICP" means infected cell polypeptide; "IL" means interleukin; "R L " means repeat length; "RNA" means ribonucleic acid; "miR" and "miRNA" mean microRNA; "R S " means repeated short; "U L "U" means unique length; S " means unique short. The names "VG2062" and "VG203" refer to the same construct and are used interchangeably.

[0062] G2062 is a recombinant HSV-1 platform that exploits dual regulation of transcription and translation (“TTDR” – see Figure 1 ) to limit viral replication to tumor cells and enhance tumor-specific toxicity without compromising safety. In addition, VG2062 expresses a payload cassette consisting of IL12, IL15, and IL15 receptor α subunits. The payload expression is under the control of the CMV promoter so that it is expressed in cells that do not suppress CMV promoter function. Finally, the viral glycoprotein B (gB) in VG2062 is truncated to promote viral spread in tumors through enhanced fusogenicity.

[0063] C. Post-transcriptional regulation

[0064] In VG2062, the expression of ICP34.5 is post-transcriptionally regulated. In brief, in wild-type HSV-1, there are 2 copies of the ICP34.5 gene. In VG2062, one copy of ICP34.5 is deleted. For the remaining ICP34.5 gene, VG2062 inserts multiple copies of the binding domain for miR124 and miR143 in the 3'UTR region to post-transcriptionally regulate its expression.

[0065] ICP34.5 is encoded by the HSV late gene g-34.5. G-34.5 is well known for its function of suppressing the antiviral immunity of host cells (especially neuronal cells) to cause neurotoxicity. In order to eliminate the function of ICP34.5 in neurons and other normal cells while retaining its activity of stable replication in tumor cells, VG2062 uses microRNA as post-transcriptional control to achieve differential expression of ICP34.5 in tumor cells, rather than controlling the expression of ICP34.5 by deleting genes or using specific promoters to target specific tumors. In short, miRNA is a non-coding small RNA of about 22 nucleotides encoded by a miRNA gene, which is transcribed by RNA polymerase II to produce primary miRNA (pri-miRNA). Mature single-stranded (ss) miRNA forms a miRNA-associated RNA-induced silencing complex (miRISC). miRNAs in miRISC may affect gene expression by binding to the 3'-noncoding region (3'-UTR) in the target mRNA. This noncoding region consists of sequences recognized by the miRNA. If the complementation of the miRNA:mRNA complex is perfect, the mRNA is degraded by Ago2, a protein belonging to the Argonaute family. However, if the complementation is not perfect, the translation of the target mRNA is not completely degraded, but is still suppressed.

[0066] miRNA is differentially expressed in a tissue-specific manner. One example is miR124. Although the precursors of miR-124 from different species are different, the sequences of mature miR-124 in humans, mice, and rats are exactly the same. MiR-124 is the most expressed miRNA in neuronal cells and is highly expressed in immune cells and organs (Qin et al., 2016, miRNA-124inimmune system and immune disorders.Frontiers in Immunology, 7 (October), 1-8). Another example of differential expression of miRNA is miR143 (Lagos-Quintana et al., 2002, Identification of tissue-specific MicroRNAs from mouse.Current Biology, 12 (9), 735-739). miR-143 is constitutively expressed in normal tissues but significantly downregulated in cancer cells (Michael et al., 2003, Reduced Accumulation of Specific MicroRNAs in Colorectal Neoplasia. Molecular Cancer Research, 1(12), 882-891).

[0067] The 3'UTR region of the ICP34.5 gene in VG2062 contains multiple copies of a binding domain (also called a "miRNA target sequence", "miRNA binding sequence" or "miRNA binding site") that is fully complementary to miR124 and miR143. Binding of miR124 and miR143 to the 3'UTR of ICP34.5 mRNA results in degradation of the mRNA; thus, the gene is post-transcriptionally downregulated in normal cells but not in tumor cells. This design allows ICP34.5 to be differentially expressed in tumor cells.

[0068] In various embodiments, the miRNA target sequence can bind to at least two different miRNAs (e.g., one or more of miR-124, miR-124, and miR-143). In certain embodiments, the miR target sequence includes SEQ ID NO.2 (miR-124 binding sequence); SEQ ID NO.3 (miR-143 binding sequence); SEQ ID NO.9 (miR-223 binding sequence); and SEQ ID NO.10 (miR-125b binding sequence). Other miRNA target sequences that can be used in other embodiments of the present invention include, for example, mlR-122, miR-127, miR-128, miR-129, miR-129*, miR-132, mlR-133a, mlR133b, miR-135b, miR-136, miR-136*, miR-137, miR-139-5p, mlR-145, miR-154, miR-184, miR-188, miR-204, mlR216a, miR-299, miR-300-3p, miR-300-5p, miR-323, miR-329, miR-337, miR-335, miR-34 1.miR-369-3p,miR-369-5p,miR-376a,miR-376a*,miR-376b-3p,miR-376b-5p,mi R-376c,miR-377,miR-379,miR-379*,miR-382,miR-382*,miR-409-5p,miR-410,m iR-411,miR-431,miR-433,miR-434,miR-451,miR-466b,miR-485,miR-495,miR-5 39. miR-541, miR-543*, miR-551b, miR-758 and miR-873, WO2020 / 113151 are incorporated herein by reference in their entirety.

[0069] D. ICP27 expression in VG2062 is under transcriptional control

[0070] HSV-1 viral replication depends on a cascade of viral gene expression, in which immediate early gene products (particularly ICP4 and ICP27) control the subsequent expression of viral early and late genes that govern the viral lytic replication cycle. Loss of ICP4 or ICP27 results in complete abrogation of viral replication and a significant reduction in viral gene expression, making ICP4 and ICP27 excellent targets for tumor-specific regulation in oncolytic HSV.

[0071] ICP4 is the main transcription factor that regulates viral gene expression, while ICP27 is a multifunctional protein that regulates the transcription of multiple viral genes. ICP27 functions at all stages of mRNA biosynthesis (from transcription, RNA processing and export, to translation). ICP27 is also closely related to nuclear protein quality control, cell cycle control, activation of stress signal transduction pathways, and prevention of apoptosis.

[0072] In VG2062, the native promoter of ICP27 was replaced with a 279 bp human CXC motif chemokine receptor 4 (CXCR4) promoter to enhance expression in urological tumors that typically have high levels of CXCR4.

[0073] E. Enhanced load expression of VG2062

[0074] VG2062 co-expresses IL12, IL15, and IL15 receptor α subunit to further stimulate immunoregulatory responses. IL12 expression promotes the polarization of antigen-exposed T cells to inflammatory and anti-tumor T cells. H 1 phenotype, while IL-15 activates NK cells to further increase tumor killing and activation of antigen-presenting cells. In addition to IL15 expression, VG2062 encodes IL15Rα to further enhance immune stimulation.

[0075] Transcription of IL-12, IL-15 and IL-15Rα, and / or antagonists of PD-1, PD-L1 and / or PD-L2 can be driven by a single strong promoter (e.g., a viral promoter such as CMV, or other strong promoters such as EF-1α or CAG, or a strong tumor-specific promoter such as CEA, CXCR4, PSA, ARR2PB, RAN or telomerase), and the polypeptide is linked to a 2A self-cleaving peptide (see SEQ ID NO. 7; see also Z. Liu et al., 2017, Systemic comparison of 2A peptides for cloning multi-genes in a polycistronic vector. Scientific Reports, 7(1), 1-9) that generates three independent proteins during translation through a ribosome skipping mechanism.

[0076] F. Truncated glycoprotein B (gB)

[0077] HSV-1 membrane fusion is a key step during infection. It depends on four essential viral glycoproteins (gB, gD, gH and gL), which mediate entry into host cells by fusing the viral envelope with the host cell membrane. The fusion protein of the core is glycoprotein B (gB), a glycosylated transmembrane protein of 904 residues encoded by the UL27 gene of HSV-1. The polymorphic mutation in the cytoplasmic domain of gB produces a superfusion expression type, which increases cell-cell fusion (Chowdary & Heldwein, 2010, Syncytial Phenotype of C0Terminally Truncated Herpes Simplex Virus Type1gB Is Associated with Diminished Membrane Interactions. Journal of Virology, 84 (10), 4923-4935). In one embodiment, gB can be modified by truncating C-terminal amino acids 877 to 904 from the full-length protein.

[0078] G. Modified ICP47 promoter

[0079] In the HSV genome, the promoter controlling the expression of the US12 gene encoding UL47 is identical to the promoter controlling the expression of the US1 gene located approximately 13k base pairs from the US12 gene. In addition, a large segment of the native ICP47 promoter includes repetitive sequences that may promote pseudohomologous recombination events. Therefore, it is predicted that replacing the native ICP47 promoter with a heterologous promoter may improve the genome stability of the virus.

[0080] In HSV, ICP27 and ICP47 are both encoded by immediate early genes, expressed very early after infection, and share multiple regulatory elements. Therefore, in order to reduce the risk of homologous recombination while maintaining the natural expression pattern, the native ICP27 promoter was used to replace the native ICP47 promoter in the VG2062 construct.

[0081] In some embodiments, the native ICP27 promoter includes the entire DNA sequence between the coding regions of UL53 (gK) and UL57 (ICP27). In one embodiment, the ICP27 promoter includes the 538 bp sequence listed in SEQ ID NO.1.

[0082] In other embodiments, the ICP27 promoter sequence may be 90%, 80%, 70%, 60% or 50% identical to the ICP27 promoter sequence of any known human herpesvirus type 1 strain or human herpes simplex virus type 2 strain, such as human herpesvirus type 1 strain 17 (NCBI reference sequence NC_001806.2).

[0083] hVG2062 is an oncolytic virus product with ICP27 under the control of the CXCR4 promoter, ICP34.5 under the control of miRNA-124 / 143, and ICP47 under the control of the ICP27 promoter. hVG2062 also contains a cytokine box encoding viral expression of IL-12, IL-15 / IL-15RA under the control of the CMV promoter. The expression control mechanism in hVG2062 is designed to increase safety without sacrificing efficacy. Specific modifications to wild-type HSV-1 strain 17+ are listed in Table 1 below.

[0084]

[0085] CEA = carcinoembryonic antigen; CXCR4 = CXC motif chemokine receptor 4; gB = glycoprotein B; HSV-1 = herpes simplex virus-1; ICP0 = infected cell polypeptide 0; ICP27 = infected cell polypeptide 27; ICP47 = infected cell polypeptide 47; ICP34.5 = infected cell polypeptide 34.5; IL = interleukin; miR = microRNA; Rα = receptor α; TR L = terminal repeat length; TR S = short terminal repeat; UL = unique long; US = unique short; LAT = latency-associated transcript.

[0086] VG2062 is a conditionally replicative oncolytic HSV-1 virus. The genome of VG2062 lacks one copy of ICP34.5, the terminal repeats of ICP0 and LAT of HSV-1 (TR L ) sequence and the short terminal repeat (TR) of HSV-1 containing one copy of ICP4 S) sequence. The remaining copies of ICP34.5 have insertions of multiple copies containing binding domains for miRNA miR-124 and miR-143 in their 3'UTR regions, which are highly expressed in neurons and normal tissues but not in tumor cells. The product is further modified by replacing the natural viral promoter of the essential viral gene UL54 encoding ICP27 (infected cell polypeptide 27) with a tumor-specific promoter from the tumor-selective CXC motif chemokine receptor 4 (CXCR4) gene. The product is further modified by replacing the natural viral promoter driving the expression of the immediate early US12 gene encoding ICP47 (infected cell polypeptide 47) with a natural viral promoter driving the expression of the immediate early UL54 gene encoding ICP27 (infected cell polypeptide 27). VG2062 also expresses a potent immunomodulatory load composed of IL-12, IL-15, and IL-15Rα, which is controlled by the cytomegalovirus (CMV promoter). Finally, VG2062 has a glycoprotein B (gB) truncation to enhance fusion activity, thereby promoting viral spread within the tumor microenvironment.

[0087] H. Therapeutic Compositions

[0088] Provided are therapeutic compositions useful for preventing, treating or alleviating diseases such as cancer. More particularly, provided are therapeutic compositions comprising at least one oncolytic virus as described herein.

[0089] In certain embodiments, the composition will further comprise a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" is intended to encompass any carrier, diluent or excipient that does not interfere with the effectiveness of the biological activity of the oncolytic virus and is non-toxic to the individual to which it is administered (see generally Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins; 21st edition May 1; 2005 and The United States Pharmacopeia: The National Formulary (USP 40-NF 35 and Supplements)).

[0090] In the case of oncolytic viruses as described herein, non-limiting examples of suitable pharmaceutical carriers include phosphate buffered saline solutions, water, emulsions (such as oil / water emulsions), various types of wetting agents, sterile solutions and other pharmaceutical carriers. Additional pharmaceutically acceptable carriers include gels, bioabsorbable matrix materials, transplant elements containing oncolytic viruses, or any other suitable vehicles, delivery or distribution methods or materials. Such carriers can be prepared by conventional methods and can be administered to individuals at effective doses. Additional pharmaceutically acceptable excipients include, but are not limited to, water, saline, polyethylene glycol, hyaluronic acid and ethanol. Pharmaceutically acceptable salts may also be included therein, such as inorganic acid salts (such as hydrochlorates, hydrobromides, phosphates, sulfates, etc.) and organic acid salts (such as acetates, propionates, malonates, benzoates, etc.). Such pharmaceutically acceptable (pharmaceutical grade) carriers, diluents and excipients that can be used to deliver oHSV to cancer cells preferably do not induce an immune response in the individual (subject) receiving the composition (and administration preferably does not bring excessive toxicity).

[0091] The compositions provided herein can be provided in various concentrations. For example, the dose of the oncolytic virus can be about 10 6 to about 10 9 In other embodiments, the dosage range may be about 10 6 to about 10 8 pfu / ml, with up to 4 ml injected into patients with larger lesions (e.g. >5 cm), and smaller amounts (e.g. up to 0.1 ml) injected into patients with smaller lesions (e.g. <0.5 cm) every 2-3 weeks of treatment.

[0092] In certain embodiments of the invention, lower than standard doses may be used. Thus, in certain embodiments, less than about 10 6 pfu / ml (up to 4 ml injected into the patient every 2-3 weeks).

[0093] The composition can be stored at a temperature conducive to a stable shelf life, including at room temperature (about 20°C), 4°C, -20°C, -80°C, and in liquid N2. Compositions for in vivo use generally do not have preservatives and are therefore typically stored at colder temperatures. The composition can be stored dry (e.g., lyophilized) or in liquid form.

[0094] I. Application

[0095] In addition to the compositions described herein, various methods of using such compositions to treat or alleviate cancer are provided, comprising the step of administering to an individual an effective dose or amount of an oHSV as described herein.

[0096] The terms "effective dose" and "effective amount" refer to an amount of oncolytic virus sufficient to effectively treat the target cancer, such as an amount that effectively reduces the target tumor size or load, or otherwise prevents the growth rate of target tumor cells. More specifically, such terms refer to an effective amount of oncolytic virus to achieve the desired result at the necessary dose and during treatment. For example, in the case of treating cancer, an effective amount of the composition described herein is an amount that causes improvement, reduces tumor burden, and / or prevents tumor spread or cancer growth. The effective amount may vary according to factors such as the individual's disease state, age, sex, and weight, as well as drug formulations, routes of administration, etc., but those skilled in the art can still determine it according to routine.

[0097] The therapeutic composition is administered to an individual diagnosed with cancer or suspected of having cancer. The individual can be a human or a non-human animal.

[0098] The composition is used to treat cancer. The term "treat / treating / treatment" as used herein means a method for obtaining a beneficial or desired result (including a clinical result). Beneficial or desired clinical results may include, but are not limited to, relief or alleviation of one or more detectable or undetectable symptoms or conditions, weakening of the extent of the disease, a stable (i.e., non-worsening) disease state, prevention of disease spread, delay or slowing of disease progression, alleviation or alleviation of the disease state, weakening of disease recurrence, and (partial or complete) improvement. The term "treatment" may also mean extending the survival period compared to the expected survival period without treatment.

[0099] Representative forms of cancer include carcinoma, leukemia, lymphoma, myeloma and sarcoma. Representative forms of leukemia include acute myeloid leukemia (AML), and representative forms of lymphoma include B cell lymphoma. Further examples include but are not limited to bile duct, brain (e.g. glioblastoma), breast, cervix, colorectum, CNS (e.g. acoustic neuroma, astrocytoma, craniopharyngioma, ependymoma, glioblastoma, hemangioblastoma, medulloblastoma, meningioma, neuroblastoma, oligodendroglioma, pinealoma and retinoblastoma), endometrial lining, hematopoietic cells (e.g. leukemia and lymphoma), kidney, bladder, larynx, lung, liver, oral cavity, ovary, pancreas, prostate, skin (e.g. melanoma and squamous cell carcinoma), GI (e.g. esophagus, stomach and colon) and thyroid cancer. Cancer can include solid tumors (e.g., sarcomas such as fibrosarcomas, myxosarcoma, liposarcoma, chondrosarcoma, and osteogenic sarcomas), be diffuse (e.g., leukemia), or some combination of the above (e.g., metastatic cancer with solid tumors and disseminated or diffuse cancer cells). Cancer can also be resistant to traditional treatments (e.g., traditional chemotherapy and / or radiation therapy). Benign tumors and other conditions with undesirable cell proliferation can also be treated.

[0100] Particularly preferred cancers to be treated include those with high levels of CXCR4 expression. Representative examples include urinary tumors, lung tumors, breast and prostate tumors, glioblastomas, tumors of the gastrointestinal tract (and related organs) such as the esophagus, bile duct carcinomas, anus, stomach, bladder, intestines, pancreas, colon and liver, and all surface injectable tumors (e.g., melanoma).

[0101] The recombinant herpes simplex virus described herein can be administered, for example, orally, topically, parenterally, systemically, intravenously, intramuscularly, intraocularly, intrathecally, intratumorally, subcutaneously or transdermally. In certain embodiments, the oncolytic virus can be delivered by intubation, by catheter or by direct injection. The site of administration can be directly applied to a site within the tumor, near the tumor or away from the tumor. The route of administration should generally depend on the type of cancer being targeted.

[0102] In the art, the attending physician can readily determine the optimal or appropriate dosage regimen for an oncolytic virus based on patient data, patient observations, and various clinical factors, including, for example, the individual's size, body surface area, age, sex, and the specific oncolytic virus being administered, the timing and route of administration, the type of cancer being treated, the patient's general health, and other drug therapies the patient is undergoing.

[0103] The recombinant herpes simplex virus described herein can be formulated as medicaments and pharmaceutical compositions for clinical use and can be combined with pharmaceutically acceptable carriers, diluents, excipients or adjuvants. The formulation will depend at least in part on the route of administration. Suitable formulations may include the virus and the inhibitor in a sterile medium. The formulation may be in the form of a fluid, gel, paste or solid. The formulation may be provided to an individual or a medical professional.

[0104] Preferably, a therapeutically effective amount is administered. This is an amount sufficient to demonstrate benefit to the individual. The actual amount administered and the timing of administration will depend, at least in part, on the nature of the cancer, the individual's condition, the site of delivery, and other factors.

[0105] In other embodiments of the present invention, the oncolytic virus provided herein may be administered together with a therapeutic agent that blocks, binds to, or inhibits CTLA-4, PD-1, or its ligand (e.g., before, simultaneously, or after). In short, CTLA-4 (or "cytotoxic T-lymphocyte-associated protein 4", also known as CD152) and PD-1 (or "programmed cell death protein 1", also known as CD279) are proteins on the surface of T cells and B cells that play a role in downregulating the immune system, thereby curbing T cell inflammatory activity and preventing or reducing the ability of the immune system to kill tumor cells.

[0106] PD-1 has two ligands: PD-L1 and PD-L2. Representative examples of PD-1, PD-L1, and PD-L2 antagonists include peptides and antibodies that statistically significantly block, bind to, or otherwise inhibit the binding of PD-1 or its ligands, thereby inhibiting or reducing their activity. Representative examples of PD-L1 antagonists include nucleic acid sequences encoding any of the following: Atezolizumab (TECENTRIQ - a humanized anti-PD-L1 antibody); Avelumab (BAVENCIO - a fully human anti-PD-L1 antibody); Durvalumab (IMFINZI - a human anti-PD-L1 antibody); Durvalumab (IMFINZI - a fully human IgG1 antibody); KN035; Cosibelimab (CK-301, from Checkpoint Therapeutics); AUNP12 (a peptide PD-1 / PD-L1 inhibitor from Aurigene and Laboratoires Pierre Fabre); CA-170; and BMC-986189 (a macrocyclic peptide).

[0107] Representative examples of PD-1 antagonists include the following representative anti-PD-1 antibodies: Nivolumab (OPDIVO – a human anti-PD-1 antibody); Pembrolizumab (KEYTRUDA – a humanized anti-PD-1 antibody); Cemiplimab (LIBTAYO – an anti-PD-1 antibody); Dostarlimab (JEMPERLI – an anti-PD-1 antibody); Vopratelimab (JTX-4014), from Jounce Therapeutics; Spartalizumab (PDR001), from Novartis; Camrelizumab (SHR1210) – an anti-PD-1 monoclonal antibody, from Jiangsu Hengrui Medicine Co., Ltd.; Sintilimab (IBI308), a human anti-PD-1 antibody developed by Innovent and Eli Lilly; Tislelizumab (BGB-A317 – a humanized IgG4 anti-PD-1 monoclonal antibody; Toripalimab (JS 001), a humanized IgG4 anti-PD-1 monoclonal antibody; INCMGA00012 (MGA012), a humanized IgG4 monoclonal antibody developed by Incyte and MacroGenics; AMP-224, from AstraZeneca / Medlmmune and GlaxoSmithKline; and AMP-514 (MEDI0680), from AstraZeneca.

[0108] Representative patents and patent applications describing PD-1, PD-L1 and PD-L2 antagonists and methods for evaluating their activity include, for example, U.S. Patent Nos. 7,595,048, 7,943,743, 8,952,136, 8,217,149, 8,609,089, 8,735,553, 8,779,105, 8,779,108, 8993731 and 9,815,897; U.S. Publication No. 2010 / 020305 6, 2010 / 0266617, 2011 / 0229461, 2013 / 0017199, 2014 / 341917, 2015 / 0203579, 2016 / 0311903, 2016 / 0376367, 2016 / 0311903, 2017 / 0044259 and 2018 / 0346569; and PCT Publication No. WO2012145493; all of which are incorporated herein by reference in their entirety.

[0109] CTLA-4 also has two major ligands: CD80 and CD86 on the surface of T cells. Representative examples of CTLA-4 antagonists include peptides and antibodies that block, bind to, or otherwise inhibit the binding of CTLA-4 or its ligands, thereby inhibiting or reducing its activity. Representative examples of CTLA-4 antagonists include: Ipilimumab (Yervoy-a fully human anti-CTLA-4 monoclonal antibody, IgG1 isotype); and Tremelimumab (Imjudo-a fully human anti-CTLA-4 antibody, IgG2 isotype). Representative examples of patents involving nucleic acid sequences encoding anti-CTLA-4 antibodies and variants thereof include U.S. Pat. Nos. 5,811,097, 5,855,887, 5,977,318, 6,051,227, 6,207,156, 6,682,736, 6,984,720, 7,109,003, 7,132,281, and 10,196,445, and PCT Publication Nos. WO 2001 / 014424, WO 2004 / 035607, and WO 2005 / 0201994, all of which are incorporated herein by reference in their entirety.

[0110] According to certain embodiments, treatment of an individual with an oncolytic virus and a CTLA-4, PD-1, PD-L1 or PD-L2 antagonist as described herein can be combined with other types of therapy, such as surgical resection, administration of a different oncolytic virus, radiation therapy, administration of a checkpoint inhibitor, chemotherapy using, for example, chemotherapeutic agents (such as etoposide, ifosfamide, doxorubicin, vincristine, doxycycline), and other therapies.

[0111] Example

[0112] Overview: All viral mutagenesis can be performed in E. coli using standard lambda red-mediated recombineering techniques implemented in viral genomes cloned into bacterial artificial chromosomes (BACs) (see generally: Tischer BK, Smith GA, Osterrieder N. Methods Mol Biol. 2010; 634:421-30. doi: 10.1007 / 978-1-60761-652-8_30. PMID: 20677001; Tischer BK, von Einem J, Kaufer B and Osterrieder N., BioTechniques 40: 191-197, February 2006 (including supplementary materials), doi: 10.2144 / 000112096; and Tischer BK, Smith, GA and Osterrieder N. Chapter 30, Jeffrey P. Braman (ed.), In Vitro Mutagenesis Protocols: 3rd edition, Methods in Molecular Biology, Volume 634, doi:10.1007 / 978-1-60761-652-8_30, Springer Science+Business Media, LLC 2010).

[0113] BAC recombineering requires the presence of exogenous BAC DNA in the viral genome to promote mutation induction in E. coli. BAC sequences are most often inserted between viral genes (such as HSV genes US1 / US2, UL3 / UL4 and / or UL50 / UL51) or inserted into the TK gene that can destroy the expression of natural thymidine kinase (TK). TK-deficient viral vectors can include an expression cassette of a copy of a natural viral thymidine kinase (TK) gene, which is under the control of a constitutive promoter inserted into the non-coding region of the viral genome. Alternatively, exogenous BAC sequences are removed via homologous recombination to restore the natural TK gene sequence, and TK function can be restored. The presence of a functional TK gene makes the virus sensitive to commonly used treatments using guanosine analogs (such as ganciclovir and acyclovir), thereby enhancing viral safety.

[0114] Example 1

[0115] Developed TTDR virus platform VG203

[0116] like Figure 1As shown, transcriptional regulation is achieved by controlling the expression of the essential HSV-1 transactivator protein ICP27 using a tumor-specific CXCR4 promoter. Translational regulation uses multiple tandem copies of microRNA binding sites inserted into the 3'-UTR of the key HSV-1 neurotoxic factor ICP34.5. ICP34.5 promotes binding to microRNAs, which are abundant in normal cells and downregulated in tumor cells. Connection to the microRNA causes reduced translation in normal cells and increased degradation of ICP34.5mRNA transcripts, while allowing ICP34.5 to continue to be produced at almost wild-type levels in tumor cells. In addition, glycoprotein B is truncated to increase fusogenicity and the CMV promoter-driven cytokine expression cassette encoding IL-12, IL-15 and IL-15α receptors is inserted between the HSV-1 genes UL3 and UL4. The natural promoter that drives ICP47 expression is also replaced by the HSV-1ICP27 promoter to reduce the risk of repetitive and non-unique ICP47 promoter region recombinant events. Wild-type HSV-1 contains two identical copies of RL (containing ICP0 and ICP34.5) and RS (containing ICP4), which promote recombination events during viral replication to produce four roughly equimolar isomers of the HSV-1 genome with opposite orientations of the US and UL regions (see generally Slobedman B, Zhang X, Simmons A. Herpes simplex virus genome isomerization: origins of adjacent long segments in concatemeric viral DNA. J Virol. 1999 January; 73(1): 810-3. doi: 10.1128 / JVI.73.1.810-813.1999. PMID: 9847394; PMCID: PMC103895). Genome linearization occurs at the RL-RS junction, and the separated RL and RS flanking the genome are often referred to as TRL (terminal repeat long) and TRS (terminal repeat short), while the unseparated internal groups of RL and RS are referred to as IRL (internal repeat long) and IRS (internal repeat short). We removed one copy of the RL and RS to reduce the probability of internal recombination and fix the viral genome to a single stable conformation, while attenuating virulence and freeing up genomic space for payload insertion.

[0117] CXCR4 = CXC motif chemokine receptor 4; gB = glycoprotein B; HSV-1 = herpes simplex virus-1; ICP0 = infected cell polypeptide 0; ICP27 = infected cell polypeptide 27; ICP47 = infected cell polypeptide 47; ICP34.5 = infected cell polypeptide 34.5; IL = interleukin; miR = microRNA; TRL = terminal repeat long; TRS = terminal repeat short; UL = unique long; US = unique short. VG2062 is the historical name of VG203 and is used interchangeably.

[0118] Example 2

[0119] MicroRNA-mediated control of viral gene expression

[0120] Objective: To study the ability of microRNA to control the expression of viral genes.

[0121] Steps: 293T cells were transfected with precursors of miR-124 and miR-143 or miR-223 and miR-125b. Transfection with missense miRs was used as a negative control. 24 hours after transfection, cells were repeatedly infected with two different clones of VG17 (wild type), VG161, mVG2031-TK, VG2062-TK or VG21224-TK. Since VG17 and VG161 do not contain exogenous miR binding sites, they are used as negative controls, while mVG2031-TK is a murine version of VG2062 containing mouse IL-12 instead of human IL-12. VG21224-TK is an alias for VG21224 (see PCT / CN2023 / 073525), and VG2062-tk is an alias for VG2062. The difference between VG21224 and VG2062 is that VG21224 has 5 tandem copies of the binding site for miR-223 and 5 tandem copies of the binding site for miR-125b located in the 3'UTR of ICP27. RNA was isolated 6 hours after infection, and RT-qPCR was performed to measure ICP27 and ICP34.5 transcript levels.

[0122] Results: Figure 2As shown in, for all viruses containing miR-124 and miR-143 binding sites in the 3'-UTR of ICP34.5 (mVG2031-TK, VG2062-TK and VG21224-TK), the presence of miR-124 and miR-143 reduced ICP34.5 transcripts by approximately 50%. Regulating ICP27 using miR-223 and miR-125b was even more effective, resulting in an almost complete reduction in ICP27 expression in both tested clones of VG21224-TK. It is noteworthy that despite the lack of miR-223 and miR-125b binding sites in the 3'-UTR of ICP34.5, miR-223 and miR-125b in VG21224-TK were even more effective than miR-124 and miR-143 in downregulating ICP34.5 transcripts, which may be due to the effective regulation of ICP27 by miR-223 and miR-125b in VG21224-TK. ICP27 is a key transactivator of other viral genes (including ICP34.5), which explains why downregulating ICP27 expression will also reduce the expression of other viral genes, ultimately leading to reduced replication efficiency in non-tumor cells expressing high levels of miR-223 and miR-125b.

[0123] Conclusion: In this experimental system, microRNA can effectively control the expression of viral genes.

[0124] Example 3

[0125] Comparison of expression patterns in cell-cell fusion

[0126] Objective: To evaluate the ability of different recombinant HSV to induce cell-cell fusion in vitro.

[0127] Procedure: Vero cell monolayers were seeded in 96-well plates and infected with VG21224 (VG202), VG2062 (VG203) and VG2063. Virus plaques were imaged at 10x magnification 3 days after infection. Unlike VG2062, VG2063 retained the native ICP47 promoter, while both VG2062 and VG21224 replaced the native ICP47 promoter with the HSV-1 ICP27 promoter.

[0128] Results: Figure 3As shown in , VG2063 exhibited only mild fusogenicity. However, when the native ICP47 promoter was replaced with the ICP27 promoter, we observed a significant and unexpected increase in cell-cell fusion, as evidenced by the presence of multiple multinucleated giant cells (syncytia) in Vero cells infected with VG21224 and VG2062. This result is significant because ICP47 has no known role in cell-cell fusion and fusogenic mutations in ICP47 have not been described.

[0129] Conclusion: Replacing the native ICP47 promoter with the native ICP27 promoter unexpectedly increased the formation of fused cells.

[0130] Example 4

[0131] HSV genome stability after multiple in vitro passages

[0132] Objective: To evaluate the stability of the UL-US junction after deletion of one copy of RL and one copy of RS between genes UL1 and US12 (ICP47). We hypothesized that replacement of the native ICP47 promoter should have a positive effect on HSV genome stability, since the promoter driving the US12 gene encoding ICP47 is identical to the promoter of the US1 gene located approximately 13 kbp on the opposite side of US12 from the US region. In addition, the native ICP47 promoter contains a large portion of repetitive sequences that can promote pseudohomologous recombination events.

[0133] Steps: The VG2062 virus containing one copy of RL and one copy of RS between genes UL1 and US12, and replacing US12 (ICP47) promoter with ICP27 promoter, was passaged multiple times on Vero cells. The stability of the DNA region between genes UL1 and US12 was determined by using primers annealing to UL1 and US12 coding regions, and by PCR amplification of the segment between genes UL1 and US12. The PCR results were compared with control viruses, which also contained one copy of RL and one copy of RS between genes UL1 and US12, but retained the natural US12 (ICP47) promoter. The control virus was also passaged multiple times on Vero cells.

[0134] Results: We did not observe changes in the electrophoretic activity of the PCR-amplified DNA fragments corresponding to the UL-US junction in VG2062 even after multiple in vitro passages. The PCR-amplified DNA fragments were also sequenced, and no changes in the DNA sequence between passages were observed. This result is in contrast to the control virus, for which the UL-US junction could not be amplified by PCR after several in vitro passages.

[0135] Conclusion: Replacement of the native ICP47 promoter with the ICP27 promoter increases the genomic stability of the HSV UL-US junction following deletion of one copy of RL and one copy of RS from the UL-US junction, which is flanked by UL1 and US12 (ICP47).

[0136] Example 5

[0137] Analysis of the regulation of HSV-1ICP27 gene by CXCR4 promoter in VG2062

[0138] Purpose: CXC motif chemokine receptor 4 (CXCR4) is implicated in tumor growth and its metastasis throughout the body. As part of the transcriptional and translational dual regulation (TTDR) strategy employed in VG2062, the native promoter of the HSV-1 gene ICP27 was replaced with a tumor-specific CXCR4 promoter. This study evaluated nine urological tumor cell lines by detecting ICP27 gene DNA to correlate VG2062 replication with CXCR4 expression in each cell line and quantifying VG2062 growth in infected cells by plaque assay.

[0139] Steps: Cell lines T24, DU145, UM-UC-3, HT-1376, 786-0, LNCap, J82, PC3 and 22Rv1 were grown in T182 culture bottles with appropriate growth media. On day 0, cells were treated with trypsin and inoculated into 24-well plates. At 0h on day 1, cells were infected with VG2062 at MOI=0.001 for 2 hours (each sample was repeated three times). Samples were collected at 2 hours, 24 hours, 48 ​​hours, 72 hours and 96 hours. Cell lysates were used for DNA / mRNA extraction and supernatants were used for virus titration. DNA and mRNA were separated according to the protocol provided by the kit supplier, and purified DNA and mRNA were eluted in 30 μl of nuclease-free water. mRNA (200ng) was reverse transcribed and cDNA was collected in 20 μl ddH2O, followed by 180 μl ddH2O 1:10 dilution. qPCR was performed on cDNA to measure CXCR4 gene expression relative to the housekeeping gene GAPDH, and qPCR was also performed on DNA to measure ICP27 gene copy number relative to GAPDH.

[0140] For the plaque assay, the infected cell supernatant was serially diluted 10-fold with serum-free medium, and 500 μl of the diluted sample was used to infect Vero cells in a 12-well plate. After 2 hours of incubation, the infected Vero cells were covered with 500 μl of gelatinous medium (MEM + 1.5% methylcellulose + 1% FBS). The plates were then placed in a CO2 incubator for 3 days, at which time the gelatinous medium was removed and discarded. 500 μl of 4% glutaraldehyde was added for 2 hours to fix the cells. 500 μl of 0.5% crystal violet solution was added to each well, and the plates were washed and air-dried. The number of plaques was counted and recorded from each well.

[0141] Results: RNA samples isolated from VG2062-infected cells were used to measure the mRNA expression of the CXCR4 gene and cellular GAPDH, while DNA samples isolated from VG2062-infected cells were used to measure the DNA content of viral ICP27 and cellular GAPDH. Samples were collected from 3 replicate wells in a 24-well plate. The average cycle threshold (Ct) was determined from 2 replicate wells from each sample. The Ct value of GAPDH was subtracted from the Ct value of CXCR4 to obtain ΔCt (CXCR4-GAPDH, 0h). The Ct value of GAPDH was subtracted from the Ct value of ICP27 to obtain the ΔCt (ICP27-GAPDH) at each time point, and the ΔCt (ICP27-GAPDH) at the 72-hour time point minus the ΔCt at the 2-hour time point was used to calculate the ΔCt (ICP27-GAPDH, 72h-2h), which corresponds to the change in the increase in viral DNA copy number.

[0142] Data were statistically analyzed after averaging 3 parallel data sets from each cell line. The correlation (R) and P value between ICP27 DNA and CXCR4 mRNA were determined using GraphPad Prism software 8.0. Figure 4 The linear fit depicted in the 9 cell lines was divided into 2 groups. Group A consisted of T24, DU145, J82 and PC3 cell lines. At 72h after infection, the viral ICP27 DNA level was positively correlated with the background level of CXCR4 mRNA in each cell line (R=0.98, P=0.0237). Group B consisted of UM-UC-3, HT-1376, 786-0, LNCap and 22Rv1 cell lines. At 72h after infection, the viral ICP27 DNA level was also positively correlated with the background level of CXCR4 mRNA in each cell line (R=0.96, P=0.0087).

[0143] The replication kinetics of VG2062 in 9 tested cell lines at 5 time points were quantified by plaque assay ( Figure 5VG2062 did not spread sufficiently on T24 cells (below the detection limit of the plaque assay: 10 PFU / mL), which is consistent with Figure 4 VG2062 was able to propagate on the other eight tumor cell lines.

[0144] Overall, the observed strong correlation between VG2062 viral DNA production and CXCR4 expression levels in infected cells strongly supports our dual regulation of transcription and translation (TTDR) strategy for recombinant OV construction.

[0145] Example 6

[0146] Cytotoxicity of VG2062 in different urological tumor cell lines

[0147] Objective: To compare the cytotoxicity of the TTDR virus VG2062 with that of the non-TTDR virus VG161 in a panel of 10 different urological tumor cell lines.

[0148] Procedure: T24, DU145, ACHN, UMUC-3, HT1376, 786-0, LNCap, J82, PC3 and Caki-1 cells were seeded into 96-well plates and treated with different MOIs of VG161 or VG2062. OD450nm was read to assess cell viability at 24h, 48h and 96h after infection.

[0149] Results: Results are provided on Figure 6 LNCap cells were highly sensitive to HSV-mediated cytotoxicity of both viruses at all time points tested, while J82 cells and Caki-1 cells were resistant to HSV-mediated cell killing even at the 96h time point. In all cell lines and time points with measurable cytotoxicity (IC50MOI<25), VG2062 virus consistently exhibited increased cell killing when compared to VG161, with VG2062 IC50MOI values ​​ranging from 2-fold lower to more than 15-fold lower than VG161.

[0150] Example 7

[0151] Quantification of cytokine cargo expression

[0152] Objective: To measure secretion of human IL-12 and human IL-15 cargo from VG161 and VG2062 virus-infected urological tumor cell lines.

[0153] Procedure: T24, DU145, ACHN, UMUC-3, HT1376, 786-0, LNCap, J82, PC3 and Caki-1 cells were seeded in 12-well plates overnight at 37°C and subsequently infected with VG161 (non-TTDR virus) or VG2062 (TTDR virus), respectively. Cell supernatants were collected and human IL 12p70 and human IL-15 / IL-15Rα were quantified by ELISA.

[0154] Results: Detectable levels of IL-12 and IL-15 were observed in all tested viruses and cell lines, but levels were generally higher in VG2062-infected cells compared with those from VG161-infected cells ( Figure 7 ).

[0155] Example 8

[0156] Evaluation of VG2062 efficacy in the A549 human lung cancer xenograft model

[0157] Objective: To evaluate the antitumor efficacy of VG2062 administered intratumorally (it) in the A549 human lung cancer xenograft model in female BALB / c nude mice.

[0158] Procedure: Twelve female BALB / c nude mice were subcutaneously transplanted with A549 cells. The mice were randomly divided into two groups, with 8 mice in the treatment group and 4 mice in the control group. The randomization day was defined as day 0. Group 2 was administered with DPBS + 7.5% glycerol (vehicle control). Group 1 received 3 doses of VG2062 (2.4×10 7 PFU / mouse / dose, 0.1 mL / animal). All animals were properly identified by markings on different body parts and housed and fed according to standard protocols. The longest diameter (mm) and shortest diameter (mm) of the tumor were measured by digital calipers at least 2 times / week. Tumor volume was calculated as TV = 0.5 × a × b 2 Calculation, where: TV = tumor volume, mm 3 ; a = longest diameter, mm; b = shortest diameter, mm. The mean tumor volume of each group was calculated and expressed as mean ± standard error of mean (SEM). P values ​​less than 0.05 were considered statistically significant.

[0159] Results: At the time of randomization (day 0), there was no statistical difference in tumor volume. During the experiment, the tumor volume of mice in the vehicle control group (group 2) continued to increase, while the tumor volume of mice in the group 2 continued to increase after three doses of 2.4×10 7PFU / mouse / dose of VG2062-treated mice maintained a relatively stable tumor volume ( Figure 8 ). Compared with the vehicle control group, the virus-treated group showed statistically significant inhibition of tumor growth at 14 days after injection and at every time point thereafter (P<0.05). VG2062 was well tolerated by mice during this study, and these data indicate that VG2062 has a significant anti-tumor effect in lung cancer cells such as A549.

[0160] Example 9

[0161] Dose escalation study in mice bearing prostate cancer PC3

[0162] Objective: To evaluate the antitumor activity of different doses of VG2062 in mice xenografted with the PC3 cell line (human prostate cancer).

[0163] Procedure: 40 SPF male nude mice (4-5 weeks old) were treated with 5×10 6 PC3 cells / mouse were subcutaneously transplanted. The inoculation site was the right side of the back of the mouse near the armpit. The mice were randomly divided into 5 groups, with 8 mice in each group. The group administration day was defined as day 0. Group 5 was administered DPBS+7.5% glycerol (vehicle control). Groups 1 to 4 were test groups that received a single intratumoral injection of VG2062 at different dose levels (0.1 mL / animal). Group 1 received 2.4×10 7 The dose of PFU / mouse was 2.4×10 6 The dose of PFU / mouse was 2.4×10 5 The dose of PFU / mouse was 2.4×10 4 PFU / mouse dose. All animals were properly identified by markings on different body parts and housed and fed according to standard protocols. The longest diameter (mm) and shortest diameter (mm) of the tumor were measured by digital calipers at least 2 times / week. Tumor volume was calculated as TV = 0.5 × a × b 2 Calculation, where: TV = tumor volume, mm 3 ; a = longest diameter, mm; b = shortest diameter, mm. The mean tumor volume of each group was calculated and expressed as mean ± standard error of the mean (SEM). P values ​​less than 0.05 were considered statistically significant.

[0164] Results: At the time of randomization (day 0), there was no statistical difference in tumor volume. The tumor volume of mice in the vehicle control group (group 5) continued to increase during the experiment - the tumor volume on day 0 was 149.85 ± 2.18 mm 3 , which grew to 3151.38±325.33 mm on the 28th day3 ( Fig. 9 In group 1 (2.4×10 7 PFU / mouse), the tumor volume was 1297.80±196.40mm on day 28. 3 In group 2 (2.4×10 6 PFU / mouse), the tumor volume was 1913.91±246.23mm on day 28. 3 In group 3 (2.4×10 5 PFU / mouse), the tumor volume was 2175.27±4292.09mm on day 28. 3 In group 4 (2.4×10 4 PFU / mouse), the tumor volume was 3032.35±422.25mm on day 28. 3 Compared with the vehicle control group, both Group 1 and Group 2 showed statistically significant inhibition of tumor growth (P<0.05). VG2062 was well tolerated by mice during this study, and these data indicate that the inhibition of tumor growth was significantly reduced at 2.4×10 6 VG2062 has a significant anti-tumor effect in prostate cancer cells such as PC3 at a starting dose of 10 PFU / mouse.

[0165] Example 10

[0166] Dose escalation study in mice bearing prostate cancer DU145

[0167] Objective: To evaluate the antitumor activity of different doses of VG2062 in mice xenografted with the DU145 cell line (human prostate cancer).

[0168] Procedure: 40 SPF nude mice were subcutaneously transplanted with DU145 cells. The mice were randomly divided into 5 groups, with 8 mice in each group. The group administration day was defined as day 0. Group 5 was administered with DPBS + 7.5% glycerol (vehicle control). Groups 1 to 4 were test groups that received a single intratumoral injection of VG2062 at different dose levels (0.1 mL / animal). Group 1 received 2.4×10 7 The dose of PFU / mouse was 2.4×10 6 The dose of PFU / mouse was 2.4×10 5 The dose of PFU / mouse was 2.4×10 4 PFU / mouse dose. All animals were properly identified by markings on different body parts and housed and fed according to standard protocols. The longest diameter (mm) and shortest diameter (mm) of the tumor were measured by digital calipers at least 2 times / week. Tumor volume was calculated as TV = 0.5 × a × b 2Calculation, where: TV = tumor volume, mm 3 ; a = longest diameter, mm; b = shortest diameter, mm. The mean tumor volume of each group was calculated and expressed as mean ± standard error of the mean (SEM). P values ​​less than 0.05 were considered statistically significant.

[0169] Results: At the time of randomization (day 0), there was no statistical difference in tumor volume. During the experiment, the tumor volume of mice in the vehicle control group (Group 5) increased at a higher rate than the tumor volume of mice treated with VG2062 ( Fig.10 ). Groups 1, 2, and 3 all demonstrated statistically significant inhibition of tumor growth compared to the vehicle control group (P<0.05). VG2062 was well tolerated by mice during this study, and these data indicate that at 2.4×10 5 VG2062 at a starting dose of 10 PFU / mouse had a significant anti-tumor effect in prostate cancer cells such as DU145.

[0170] Embodiment 11

[0171] Treatment of nude mice bearing UM-UC-3 bladder cancer

[0172] Objective: To evaluate the efficacy of VG2062 in a xenograft model of UM-UC-3 human bladder cancer cells.

[0173] Procedure: 24 SPF female nude mice were cultured at 5×10 6 UM-UC-3 cells / mouse (5×10 7 The mice were subcutaneously transplanted with 2.4×10 cells / mL, 0.1 mL / mouse) and randomly divided into 3 groups, with 8 mice in each group. Group 1 was administered with DPBS+7.5% glycerol (vehicle control). Groups 2 and 3 were administered with 2.4×10 7 PFU / mouse or 2.4×10 5 PFU / mouse received a single dose of VG2062 in high and low dose test groups. The administration direction of all test groups was intratumoral injection. All animals were properly identified by markings on different body parts and housed and fed according to standard protocols. The longest diameter (mm) and shortest diameter (mm) of the tumor were measured by digital calipers at least 3 times / week. Tumor volume was calculated by TV = 0.5 × a × b 2 Calculation, where: TV = tumor volume, mm 3 ; a = longest diameter, mm; b = shortest diameter, mm. The mean tumor volume of each group was calculated and expressed as mean ± standard error of the mean (SEM). P values ​​less than 0.05 were considered statistically significant.

[0174] Results: Based on the tumor volume results on day 17, G2 (VG2062, 2.40×10 7 There was a statistically significant difference in tumor volume between the ) group and the vehicle control group (P = 0.000). Fig.11 ). All 8 mice in Group 2 and 7 mice in Group 3 had complete tumor regression on day 17, while none of the animals in Group 1 showed tumor regression. VG2062 was well tolerated by mice during this study, and these data indicate that VG2062 has a significant anti-tumor effect in bladder cancer cells such as UM-UC-3.

[0175] Example 12

[0176] Evaluation of the efficacy of VG2062 in the BT-474 human breast cancer xenograft model

[0177] Objective: CXCR4 is widely involved in the progression of breast cancer and other malignancies. CXCR4 expression in breast cancer is associated with aggressiveness and poor prognosis. The aim of this study was to evaluate the antitumor efficacy of intratumorally (it) administered VG2062 in the BT-474 human breast cancer xenograft model in female BALB / c nude mice.

[0178] Procedure: 24 female BALB / c nude mice were subcutaneously implanted with BT-474 cells. The mice were randomly divided into 3 groups, with 8 mice in each group. The randomization day was defined as day 0. Group 1 was administered with DPBS + 7.5% glycerol (vehicle control). Groups 2 and 3 were test groups that received multiple intratumoral injections of VG2062 at two different dose levels (0.1 mL / animal). Group 2 received 3 doses of 1×10 5 PFU / mouse / dose. Group 3 received 3 doses of 1×10 7 PFU / mouse / dose. All animals were properly identified by markings on different body parts and housed and fed according to standard protocols. The longest diameter (mm) and shortest diameter (mm) of the tumor were measured by digital calipers at least 2 times / week. Tumor volume was calculated as TV = 0.5 × a × b 2 Calculation, where: TV = tumor volume, mm 3 ; a = longest diameter, mm; b = shortest diameter, mm. The mean tumor volume of each group was calculated and expressed as mean ± standard error of the mean (SEM). P values ​​less than 0.05 were considered statistically significant.

[0179] Results: At the time of randomization (day 0), there was no statistical difference in tumor volume. During the experiment, the tumor volume of mice in the vehicle control group (group 1) continued to increase, while the tumor volume of mice in the control group (group 1) continued to increase after 3 doses of 1×10 5PFU / mouse / dose and 3 doses of 1×10 7 The tumor volumes of mice treated with VG2062 at PFU / mouse / dose remained relatively stable and decreased, respectively ( Fig.12 ). Both Group 2 and Group 3 showed statistically significant inhibition of tumor growth compared to the vehicle control group (P<0.05). VG2062 was well tolerated by mice during this study, and these data indicate that VG2062 has a significant anti-tumor effect in breast cancer cells such as BT-474.

[0180] Embodiment 13

[0181] Treatment of mice bearing breast cancer EMT-6 with mVG2031

[0182] Objective: To evaluate the effect of mVG2031, a murine version of VG2062 in which human IL-12 is replaced by murine IL-12, on the growth inhibition of the murine breast cancer cell line EMT-6 in immunocompetent BALB / c mice implanted subcutaneously with this tumor line.

[0183] Procedure: 24 female BALB / c mice with immune competence were subcutaneously transplanted with EMT-6 cells. The mice were randomly divided into 3 groups, with 8 mice in each group. The randomization day was defined as day 0. Group 1 was administered with DPBS + 7.5% glycerol (vehicle control). Groups 2 and 3 were test groups that received multiple intratumoral (it) injections of mVG2031 at two different dose levels (0.1 mL / animal). Group 2 received 3 doses of 1×10 6 PFU / mouse / dose. Group 3 received 3 doses of 1×10 7 PFU / mouse / dose. All animals were properly identified by markings on different body parts and housed and fed according to standard protocols. The longest diameter (mm) and shortest diameter (mm) of the tumor were measured by digital calipers at least 2 times / week. Tumor volume was calculated as TV = 0.5 × a × b 2 Calculation, where: TV = tumor volume, mm 3 ; a = longest diameter, mm; b = shortest diameter, mm. The mean tumor volume of each group was calculated and expressed as mean ± standard error of the mean (SEM). P values ​​less than 0.05 were considered statistically significant.

[0184] Results: At the time of randomization (day 0), there was no statistical difference in tumor volume. During the experiment, the tumor volume of mice in the vehicle control group (group 1) continued to increase, while the tumor volume of mice in the control group (group 1) continued to increase after 3 doses of 1×10 6 PFU / mouse / dose and 3 doses of 1×107 The tumor volume of mice treated with mVG2031 remained relatively stable (PFU / mouse / dose) Fig.13 ). Both Group 2 and Group 3 showed statistically significant inhibition of tumor growth compared to the vehicle control group (P<0.05). Mice tolerated mVG2031 well during this study, and these data indicate that mVG2031 has a significant anti-tumor effect in breast cancer cells such as EMT-6.

[0185] Embodiment 14

[0186] Treatment of mice bearing breast cancer EMT-6 with a combination of mVG2031 and anti-PD-1

[0187] Objective: Co-administration of OVs with checkpoint inhibitors is an emerging treatment modality that has the potential to enhance the efficacy of oncolytic virotherapy. This study aimed to evaluate the effect of mVG2031 in combination with a checkpoint inhibitor (anti-PD-1 antibody) on the growth of the murine breast cancer cell line EMT-6 in immunocompetent BALB / c mice subcutaneously transplanted with this tumor cell line. mVG2031 is the murine version of VG2062, in which human IL-12 is replaced by murine IL-12.

[0188] Steps: EMT-6 cells were subcutaneously transplanted into 32 female BALB / c mice with immune competence. Mice were randomly divided into 4 groups, with 8 mice in each group. The random grouping day was defined as day 0. DPBS+7.5% glycerol was administered intratumorally in the first group (vehicle control). The second group was treated intratumorally with 3 doses of mVG2031 (1×10 6PFU / mouse / dose) on days 1, 2 and 3. The third group was injected intraperitoneally with anti-PD-1 antibodies twice a week at 10 mg / kg. The fourth (combination treatment) group was treated intratumorally with 3 doses of mVG2031 (1×10 6PFU / mouse / dose) on days 1, 2 and 3, and anti-PD-1 antibodies were also injected intraperitoneally twice a week at 10 mg / kg. All animals were appropriately identified by markings on different body parts and housed and fed according to standard protocols. The longest diameter (mm) and shortest diameter (mm) of the tumor were measured by digital calipers at least 2 times / week. Tumor volume was calculated as TV = 0.5 × a × b 2 Calculation, where: TV = tumor volume, mm 3 ; a = longest diameter, mm; b = shortest diameter, mm. The mean tumor volume of each group was calculated and expressed as mean ± standard error of the mean (SEM). P values ​​less than 0.05 were considered statistically significant.

[0189] Results: At the time of randomization (day 0), there was no statistical difference in tumor volume. During the experiment, the tumor volume of the two control groups without virus (vehicle and anti-PD-1 only) continued to increase, while the tumor volume of mice treated with mVG2031 (co-administered with or without anti-PD-1) was greatly reduced ( Fig.14 ). Both viral treatment groups showed statistically significant inhibition of tumor growth compared to the non-viral treatment control group (P<0.05). Notably, tumors were almost completely remitted in animals treated with a combination of virus and checkpoint inhibitors, demonstrating that the combination of virus + anti-PD-1 produces a stronger anti-tumor effect than virus treatment alone. Mice tolerated mVG2031 well during this study, and these data suggest that combining mVG2031 with checkpoint inhibitors such as anti-PD-1 antibodies has a significant anti-tumor effect in breast cancer cells such as EMT-6.

[0190] Embodiment 15

[0191] Mice bearing renal carcinoma Renca were treated with mVG2031

[0192] Objective: To evaluate the effect of mVG2031, a murine version of VG2062 in which human IL-12 is replaced by murine IL-12, on the growth inhibition of the murine renal carcinoma cell line Renca in immunocompetent BALB / c mice implanted subcutaneously with this tumor line.

[0193] Procedure: 50 SPF female nude mice (5-6 weeks old) were treated with 1×10 6 Renca cells / mouse were implanted subcutaneously. The inoculation site was the right side of the back of the mouse near the axilla. Tumor growth was monitored and tumors were transplanted when they grew to an average volume of about 100-120 mm 3 At 25 tumor-bearing mice, 25 mice were randomly divided into 5 groups according to tumor volume and body weight, with 5 mice in each group. The group administration day was defined as day 0. Group 5 was administered DPBS + 7.5% glycerol (vehicle control). Groups 1 to 4 were test groups that received one or three intratumoral injections of mVG2031 at two different dose levels. Group 1 received a single dose of 5.2×10 5 PFU / mouse. Group 2 received a single dose of 5.2×10 7 PFU / mouse. Group 3 received 3 doses of 5.2×10 5 PFU / mouse. Group 4 received 3 doses of 5.2×10 7PFU / mouse. All animals were properly identified by markings on different body parts and housed and fed according to standard protocols. The longest diameter (mm) and shortest diameter (mm) of the tumor were measured by digital calipers at least 2 times / week. Tumor volume was calculated as TV = 0.5 × a × b 2 Calculation, where: TV = tumor volume, mm 3 ; a = longest diameter, mm; b = shortest diameter, mm. The mean tumor volume of each group was calculated and expressed as mean ± standard error of the mean (SEM). P values ​​less than 0.05 were considered statistically significant.

[0194] Results: During the experiment, there was no statistical difference in tumor volume on day 0. The tumor volume of the vehicle control group (Group 5) continued to increase, and on day 21, the tumor volume of Group 5 reached 1204.23±253.76mm 3 ( Fig.15 ). This shows that the mouse renal cancer cell line Renca was successfully established in a subcutaneous transplantation tumor model using BALB / c mice. mVG2031 also showed a dose-dependent inhibition of tumor growth in the Renca model. 5 PFU / animal, single dose), the tumor volume reached 911.45±143.31mm on day 21. 3 In group 2 (5.2 × 10 7 PFU / animal, single dose), the tumor volume reached 542.27 ± 174.45 mm on day 21. 3 In group 3 (5.2×10 5 PFU / animal, 3 doses), the tumor volume reached 567.49±133.36mm on day 21. 3 In group 4 (5.2×10 7 PFU / animal, 3 doses), the tumor volume reached 337.03±95.93mm on day 21. 3 There was no statistically significant difference in tumor volume in Group 1, but the reduction in tumor volume observed in Groups 2, 3, and 4 was statistically significant beyond the threshold (P<0.05). These data indicate that mVG2031 has a significant anti-tumor effect in renal cancer cells such as Renca.

[0195] Example 16

[0196] Mice bearing bilateral renal carcinoma Renca were treated with a combination of mVG2031 and anti-PD-1

[0197] Objective: Co-administration of OVs with checkpoint inhibitors is an emerging treatment modality that has the potential to enhance the efficacy of oncolytic virotherapy. This study aimed to evaluate the effect of mVG2031 in combination with a checkpoint inhibitor (anti-PD-1 antibody) on the growth inhibition of the murine renal carcinoma cell line Renca in immunocompetent BALB / c mice subcutaneously transplanted with this tumor line. The bilateral Renca tumor model was used to evaluate remote tumor clearance. mVG2031 is a murine version of VG2062, in which human IL-12 is replaced by murine IL-12.

[0198] Procedure: Renca cells were transplanted subcutaneously in the left and right flanks of 24 immunocompetent female BALB / c mice. The mice were randomly divided into 4 groups, with 6 mice in each group. The randomization day was defined as day 0. One group was intratumorally administered DPBS + 7.5% glycerol (vehicle control) into the right flank tumor. The second group was intraperitoneally administered 10 mg / kg of anti-PD-1 antibody twice a week. The third group was intratumorally injected (into the right tumor) with mVG2031 (5×10 7 The fourth group was similarly injected with mVG2031 (5×10 7 PFU / mouse / dose), and also 10 mg / kg of anti-PD-1 antibody was administered intraperitoneally twice a week. All animals were properly identified by markings on different body parts, and were housed and fed according to standard protocols. The longest diameter (mm) and shortest diameter (mm) of the tumor were measured by digital calipers at least 2 times / week. Tumor volume was calculated by TV = 0.5 × a × b 2 Calculation, where: TV = tumor volume, mm 3 ; a = longest diameter, mm; b = shortest diameter, mm. The mean tumor volume of each group was calculated and expressed as mean ± standard error of the mean (SEM). P values ​​less than 0.05 were considered statistically significant.

[0199] Results: At the time of randomization (day 0), there was no statistical difference in tumor volume on both flanks. During the experiment, the tumor volume of all tumors on the non-injected side and the tumor volume of the two control groups (vehicle group and anti-PD-1 group) without virus on the injected side continued to increase, but only the tumor on the injected side treated with anti-PD-1 remained significantly smaller than the tumor treated with vehicle control ( Fig.16A and 16B). In mice treated with mVG2031 (co-administered with or without anti-PD-1), the tumor volume on the injected side was greatly reduced. Both groups treated with mVG2031 showed statistically significant inhibition of tumor growth on the injected side compared to the non-viral treatment control group (P<0.05). When compared to mice treated with vehicle control, only the group treated with both mVG2031 and anti-PD-1 achieved a statistically significant reduction in tumors on the non-injected side. Mice tolerated mVG2031 well during this study, and these data indicate that mVG2031 combined with checkpoint inhibitors such as anti-PD-1 antibodies has a significant anti-tumor effect in renal cancer cells such as Renca.

[0200] Embodiment 17

[0201] Treatment of nude mice bearing renal carcinoma A498

[0202] Objective: To evaluate the antitumor activity of VG2062 in a human renal cancer A498 cell line-derived xenograft (CDX) model.

[0203] Procedure: 24 SPF female nude mice were treated with 1×10 7 A498 cells / mouse were subcutaneously transplanted and randomly divided into 3 groups, with 8 mice in each group. The randomization day was marked as day 0. Group 1 was administered with DPBS + 7.5% glycerol (vehicle control). Groups 2 and 3 were administered with 2.4×10 5 PFU / mouse / dose or 2.4×10 7 PFU / mouse / dose Low and high dose measurement test groups received multiple doses of VG2062. Doses were administered on days 0, 7, 10, 11 and 12. All test groups were administered via intratumoral injection. All animals were properly identified by markings on different body parts and housed and fed according to standard protocols. The longest diameter (mm) and shortest diameter (mm) of the tumor were measured by digital calipers at least 2 times / week. Tumor volume was calculated by TV = 0.5 × a × b 2 Calculation, where: TV = tumor volume, mm 3 ; a = longest diameter, mm; b = shortest diameter, mm. The mean tumor volume of each group was calculated and expressed as mean ± standard error of the mean (SEM). P values ​​less than 0.05 were considered statistically significant.

[0204] Results: The experiment was completed on day 21 after the first treatment administration and the mean tumor volume of tumor-bearing mice in the vehicle control group was recorded as 1873.58 ± 261.30 mm 3The tumor volumes in the VG2062 high-dose group and the VG2062 low-dose group were 1068.56±157.43mm 3 and 1284.69±108.84mm 3 ( Fig.17 ). Each virus-treated group showed statistically significant inhibition of tumor growth compared to the vehicle control group (P<0.05). VG2062 was well tolerated by mice during this study, and these data indicate that VG2062 has a significant anti-tumor effect in renal cancer cells such as A498.

[0205] Embodiment 18

[0206] Corneal inoculation in the BALB / c mouse model

[0207] Objective: To evaluate the ocular pathogenicity of VG2062 after corneal inoculation in a BALB / c mouse model.

[0208] Procedure: SPF grade 8-week-old female BALB / c mice were randomly divided into 4 groups. Mice were anesthetized by injecting 10 mg of ketamine hydrochloride / 100 g body weight into the hind leg muscle. The left and right corneas were gently scratched with an insulin needle to avoid corneal rupture. 5 μl of virus solution was applied to the scratched left and right eyes. One group received 10 5 PFU / mouse of VG2062, and the other group received 10 7 PFU / mouse of VG2062, and the third group received 10 5 PFU / mouse of wild-type HSV-1 control virus strain 17+, and a fourth group received a vehicle control consisting of Vero cell supernatant (5 μl / eye).

[0209] Results: Corneal scratching is an effective method to determine HSV-1 infection. 5 PFU / mouse of wild-type HSV-1 17+ resulted in severe ocular inflammation, including difficulty opening the eyes and hair loss around the eyes. In contrast, mice infected with VG2062 showed no ocular inflammation even after 10 7 The much higher dose of 1 PFU / mouse also showed minimal ocular disease, with no significant differences in ocular pathology compared to mice treated with vehicle controls ( Fig.18 ).

[0210] The following are some exemplary numbered embodiments of the present invention.

[0211] 1. A recombinant herpes simplex virus, comprising a modified oncolytic herpes virus genome, wherein the modified herpes virus genome comprises at least one miRNA target sequence operably connected to the first copy of the ICP34.5 gene, and the second copy of the ICP34.5 gene comprises an inactivation mutation, further comprising replacing the ICP47 promoter with an immediate early gene promoter (such as an ICP4, ICP0 or ICP27 regulatory sequence operably connected to the ICP47 gene), and wherein the ICP47 gene comprises an inactivation deletion in a natural ICP47 regulatory sequence. In another embodiment, the immediate early gene promoter may be selected from HSV-1 or HSV-2.

[0212] 2. The recombinant herpes simplex virus of embodiment 1, further comprising a deletion of one RL and one RS region of the viral genome. In an optional embodiment, the mutation is a deletion of the second copy of the ICP34.5 gene.

[0213] 3. The recombinant herpes simplex virus of any one of embodiments 1 or 2, comprising two to ten miRNA target sequences operably linked to the first copy of the ICP34.5 gene. In other embodiments, the miRNA target sequences are inserted in series into the 3' untranslated region. In various embodiments, connexon DNAs of the same or different lengths may be inserted between different miRNA binding sites. In certain embodiments, the connexon is within the range of 1 to 50 base pairs. In other embodiments, the connexon is less than 10 base pairs.

[0214] 4. The recombinant herpes simplex virus of any one of embodiments 1, 2 or 3, wherein the miRNA target sequence is inserted into the 3' untranslated region of the first copy of the ICP34.5 gene.

[0215] 5. The recombinant herpes simplex virus of any one of embodiments 1, 2, 3 or 4, wherein the two to ten miRNA target sequences bind to at least two different miRNAs.

[0216] 6. The recombinant herpes simplex virus of any one of embodiments 1, 2, 3, 4 or 5, wherein the miRNA is selected from the group consisting of miR-124, miR-124* and miR-143.

[0217] 7. The recombinant herpes simplex virus of any one of embodiments 1, 2, 3, 4, 5 or 6, wherein the modified herpes virus genome comprises additional mutations or modifications in viral genes ICP0, ICP4 and / or ICP27. In additional embodiments, the mutations or modifications may comprise the deletion of one copy of RL or RS.

[0218] 8. The recombinant herpes simplex virus of any one of embodiments 1, 2, 3, 4, 5, 6 or 7, wherein the modification comprises replacing the native viral promoter with a tumor-specific promoter.

[0219] 9. The recombinant herpes simplex virus of any one of embodiments 1, 2, 3, 4, 5, 6, 7, or 8, wherein the modification is to optionally replace the entire promoter regulatory region of ICP27 with a tumor-specific promoter.

[0220] 10. The recombinant herpes simplex virus of any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8 or 9, wherein the ICP27 promoter is replaced by a CXCR4 promoter.

[0221] 11. A recombinant herpes simplex virus as described in any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, further comprising at least one nucleic acid encoding a non-viral protein selected from the group consisting of an immunostimulatory factor, an antibody and a checkpoint blocking peptide, wherein the at least one nucleic acid is operably linked to a universal or tumor-specific promoter. Examples of universal promoters include constitutive promoters such as SV40, CMV, UBC, EF1α, PGK and CAGG.

[0222] 12. A recombinant herpes simplex virus as described in any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9 or 11, wherein the non-viral protein is IL12, IL15, IL15 receptor α subunit, CTLA-4 antagonist, PD-1 antagonist, PD-L1 antagonist and / or PD-L2 antagonist. In certain embodiments, the herpes simplex virus encodes IL12, IL15, IL15 receptor α subunit, and PD-1 antagonist, such as Pembrolizumab.

[0223] 13. The recombinant herpes simplex virus of any one of embodiments 11 or 12, wherein the promoter is a CMV promoter.

[0224] 14. A recombinant herpes simplex virus as described in any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13, having a nucleic acid sequence encoding a glycoprotein with enhanced fusogenicity (compared to similar wild-type viruses). Examples include a variety of transgenics (e.g., fusion glycoproteins from gibbon ape leukemia virus "GALV") and / or mutations that enhance HSV fusion, including, for example, truncations or mutations in glycoprotein B, glycoprotein K and / or UL20. In a preferred embodiment, the nucleic acid sequence encodes a fusion form of glycoprotein B (e.g., glycoprotein B truncated after amino acid 876). In another embodiment, replacing the ICP47 promoter with the ICP27 promoter can be used to increase fusogenicity.

[0225] 15. The recombinant herpes simplex virus of embodiment 14, wherein the glycoprotein B may be truncated, wherein the deletion occurs after amino acid 876.

[0226] 16. A recombinant herpes simplex virus as described in any one of embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15, wherein the oncolytic herpes virus is HSV-1. In a particularly preferred embodiment of the present invention, the recombinant herpes simplex virus comprises an oncolytic HSV-1, wherein: a) there is a deletion of one RL containing genes encoding ICP0 and ICP34.5 and a deletion of one RS containing genes encoding ICP4; b) the natural ICP27 promoter is replaced by the CXCR4 promoter; c) a binding site for miR-143 and miR-124 is inserted in the ICP34.5 3'UTR; d) a deletion of a portion of the 3' end of the glycoprotein B coding region (e.g., an 84 bp deletion); e) an expression cassette capable of expressing IL-12, IL-15 and IL-15Rα under the control of the CMV promoter is inserted; and f) the natural ICP47 regulatory sequence is replaced by the ICP27 regulatory sequence.

[0227] Wherein the mutation is a deletion of one RL and one RS region of the viral genome. In an optional embodiment, the mutation is a deletion of the second copy containing the ICP34.5 gene.

[0228] 17. A method for inhibiting or lysing tumor cells, comprising providing a therapeutically effective amount of the recombinant herpes simplex virus of any one of embodiments 1 to 16.

[0229] 18. A method for inhibiting tumor cells, comprising providing a therapeutically effective amount of the recombinant herpes simplex virus of any one of embodiments 1 to 17 to tumor cells.

[0230] 19. The method of embodiment 18, further comprising the step of providing a CTLA-4, PD-1, PD-L1 and / or PD-L2 antagonist to the cells. In certain embodiments, the antagonist is selected from the group consisting of Ipilimumab, Tremelimumab, Pembrolizumab, Cemiplimab, Dostarlimab, Vopratelimab, Spartalizumab and Camrelizumab.

[0231] 20. A therapeutic composition comprising the recombinant herpes simplex virus of any one of embodiments 1 to 17 and a pharmaceutically acceptable carrier.

[0232] 21. The therapeutic composition of embodiment 20, further comprising a CTLA-4, PD-1, PD-L1 and / or PD-L2 antagonist. In certain embodiments, the antagonist is selected from the group consisting of Ipilimumab, Tremelimumab, Pembrolizumab, Cemiplimab, Dostarlimab, Vopratelimab, Spartalizumab and Camrelizumab.

[0233] 22. A method of treating cancer in an individual suffering from cancer, comprising the step of administering a therapeutically effective amount of the composition of embodiment 20.

[0234] 23. A method as described in embodiment 22, wherein the cancer expresses high levels of biomarkers, such as CXCR4. In other embodiments, the cancer expresses high levels of biomarkers, and its promoter is used to drive the ICP4 and / or ICP27 genes as described in any of the preceding embodiments. In other embodiments, the cancer expresses high levels of biomarkers, such as CEA or CXCR4. In certain embodiments, the cancer is selected from the group consisting of cancers of the urinary system, cervix, esophagus, lung, colorectum, stomach, bile duct carcinoma, and pancreas. In other embodiments, the cancer is selected from the group consisting of breast and prostate tumors, and glioblastoma. In other embodiments, the cancer is leukemia or lymphoma. In other embodiments, the cancer is acute myeloid leukemia (AML) or B-cell lymphoma. In other embodiments, the cancer is a surface injectable tumor. In yet other embodiments, the cancer expresses high levels of CXCR4.

[0235] 24. The method of embodiment 22, wherein the cancer is a urological cancer.

[0236] 25. The method of embodiment 22, further comprising the step of administering to the individual a CTLA-4, PD-1, PD-L1 and / or PD-L2 antagonist. In certain embodiments, the antagonist is selected from the group consisting of Ipilimumab, Tremelimumab, Pembrolizumab, Cemiplimab, Dostarlimab, Vopratelimab, Spartalizumab and Camrelizumab.

[0237] 26. A method as described in embodiment 19, wherein the cancer expresses high levels of biomarkers, and its promoter is used to drive the ICP4 and / or ICP27 genes as described in any of the preceding embodiments. In other embodiments, the cancer expresses high levels of biomarkers, such as CEA or CXCR4. In certain embodiments, the cancer is selected from the group consisting of cancers of the urinary system, cervix, esophagus, lung, colorectum, stomach, bile duct carcinoma and pancreas. In other embodiments, the cancer is selected from the group consisting of breast and prostate tumors, and glioblastoma. In other embodiments, the cancer is leukemia or lymphoma. In other embodiments, the cancer is acute myeloid leukemia (AML) or B-cell lymphoma. In other embodiments, the cancer is a surface injectable tumor. In yet other embodiments, the cancer expresses high levels of CXCR4.

[0238] The invention has been described broadly and generally herein. Narrower species and subgeneric groupings falling within the general disclosure each also form a part of the invention. This includes the general description of the invention, limitations thereof, or negative limitations removing any object from that genus, whether or not the deleted material is specifically recited herein.

[0239] It should also be understood that, unless the context clearly dictates otherwise, as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural references, the term "X and / or Y" means "X" or "Y" or both "X" and "Y", and the letter "s" after a noun indicates both the plural and singular forms of that noun. In addition, when features or aspects of the invention are described in terms of Markush groups, it is intended and those skilled in the art will recognize that the invention encompasses any individual member and any subgroup of members of the Markush group while described therein, and the applicant reserves the right to amend the application or the claims to specifically refer to any individual member or any subgroup of members of the Markush group.

[0240] It should be understood that the terms used herein are for the purpose of describing specific embodiments only and are not intended to be limiting. It should be further understood that unless specifically limited herein, the terms used herein have their conventional meanings known in the relevant art.

[0241] References throughout this specification to "one or an embodiment" and variations thereof mean that a particular characteristic, structure, or feature described in conjunction with that embodiment is included in at least one embodiment. Thus, the phrase "in one embodiment" appearing at various locations throughout this specification does not necessarily refer to the same embodiment. Furthermore, particular characteristics, structures, or features may be combined in any suitable manner in one or more embodiments.

[0242] Unless the content and context clearly dictate otherwise, the singular forms "a", "an" and "the" used in this specification and the appended claims include plural referents, i.e., one or more. It should also be noted that the connective terms "and" and "or" are generally used in the broadest sense including "and / or", unless the content and context clearly indicate inclusivity or exclusivity as the case may be. Therefore, the use of optional items (such as "or") should be understood to mean one, two, or any combination of the optional items. In addition, when described in the form of "and / or" in this article, the "and" and "or" therein are intended to cover an embodiment including all relevant items or concepts, as well as one or more other alternative embodiments including less than all relevant items or concepts.

[0243] Throughout this specification and the claims that follow, the word "comprise" and its synonyms and variations (e.g., "have" and "include") and variations thereof (e.g., "comprises" and "comprising") should be interpreted in an open, inclusive sense, e.g., "including but not limited to," unless the context requires otherwise. The term "consisting essentially of limits the claim scope to the specified materials or steps, or materials or steps that do not materially affect the basic and novel characteristics of the claimed invention.

[0244] Any title used in this article is only used to speed up the reader's browsing and should not be interpreted as limiting the present invention or claims in any way. Therefore, the title and invention abstract provided herein are only for convenience and do not explain the scope or meaning of the implementation mode.

[0245] When a numerical range is provided herein, it should be understood that, unless the context clearly dictates otherwise, each value between the upper and lower limits of the range (to one tenth of the unit of the lower limit), and any other stated value or values ​​therebetween within the stated range are included in the present invention. Subject to explicit exclusions and limits in the stated range, the upper and lower limits of the smaller range that may be independently included in the smaller range are also included in the present invention. When the stated range includes one or both of the limits, the range that does not include either or both of the included limits is also included in the present invention.

[0246] For example, any concentration range, percentage range, ratio range, or integer range provided herein should be understood to include any integer value and fractions thereof (where appropriate) (such as tenths and hundredths of integers) within the recited range, unless otherwise indicated. In addition, any numerical range related to any physical property such as polymer subunits, size, or thickness recited herein should be understood to include any integer within the recited range, unless otherwise indicated. The term "about" as used herein means ±20% of a specified range, value, or structure, unless otherwise indicated.

[0247] All U.S. patents, U.S. patent application disclosures, U.S. patent applications, foreign patents, foreign patent applications, and non-patent publications mentioned in this specification and / or listed in the application data sheet are incorporated herein by reference in their entirety. Such documents can be incorporated by reference for description and disclosure purposes, such as materials and methods described in publications that can be used in combination with the invention currently described. Publications described above and throughout this article are provided only for their disclosures before the filing date of this application. Any content herein should not be interpreted as admitting that the inventor cannot obtain any prior invention rights with reference to the disclosure.

[0248] All patents, publications, scientific papers, websites and other documents and materials referenced or mentioned herein indicate the level of technical personnel in the field to which the present invention relates, and each document and material referenced is incorporated herein by reference to the same extent as if each was incorporated herein by reference in its entirety or described herein as a whole. The applicant reserves the right to incorporate any and all materials and information entities from any of the above patents, publications, scientific papers, websites, information that can be obtained electronically, and other reference materials or documents into this specification.

[0249] In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which the claims are entitled. Therefore, the claims should not be limited by the disclosure.

[0250] In addition, the written description of this patent includes all claims. In addition, all claims (including all original claims and all claims from any and all priority documents) are incorporated by reference in their entirety into the written description of this specification, and applicants reserve the right to incorporate any and all of the above claims in substance into the written description or any other part of this application. Thus, for example, in no case can this patent be construed as not providing a written description of the claims because the exact wording of the claims does not set forth this claim in the written description of the patent in the same wording.

[0251] The claims will be interpreted in accordance with the law. However, and regardless of the alleged or perceived ease or difficulty of interpreting any claim or portion thereof, any adjustment or modification of the claims or any portion thereof during the prosecution of this application shall in no circumstances cause this patent to be interpreted as having lost any right to any and all equivalents thereof and not forming part of the prior art.

[0252] Other non-limiting embodiments are within the following claims. The patent shall not be construed as limited to the specific embodiments or non-limiting embodiments or methods specifically and / or expressly disclosed herein. In no event shall the patent be construed as limited by any statement made by any examiner or any other officer or employee of the Patent and Trademark Office unless such statement is specifically and without limitation or reservation expressly adopted by the applicant in a responding document.

Claims

1. A recombinant herpes simplex virus comprising a modified oncolytic herpes virus genome, wherein the modified herpes virus genome comprises at least one miRNA target sequence operably linked to a first copy of an ICP34.5 gene, and the second copy of the ICP34.5 gene comprises an inactivating mutation, further comprising replacing the ICP47 promoter with an immediate early gene promoter, such as an ICP4, ICP0 or ICP27 regulatory sequence operably linked to an ICP47 gene, and wherein the ICP47 gene comprises an inactivating deletion in a native ICP47 regulatory sequence.

2. The recombinant herpes simplex virus of claim 1, further comprising a deletion of one RL and one RS region of the viral genome.

3. The recombinant herpes simplex virus of claim 1, comprising two to ten miRNA target sequences operably linked to the first copy of the ICP34.5 gene.

4. The recombinant herpes simplex virus of claim 3, wherein the miRNA target sequence is inserted into the 3' non-coding region of the first copy of the ICP34.5 gene.

5. The recombinant herpes simplex virus of claim 3, wherein the two to ten miRNA target sequences bind to at least two different miRNAs.

6. The recombinant herpes simplex virus of claim 5, wherein the miRNA is selected from the group consisting of miR-124, miR-124* and miR-143.

7. The recombinant herpes simplex virus of claim 1, wherein the modified herpes virus genome comprises additional mutations or modifications in the viral genes ICP0, ICP4 and / or ICP27.

8. The recombinant herpes simplex virus of claim 1, wherein the virus is modified by replacing the native viral promoter with a tumor-specific promoter.

9. The recombinant herpes simplex virus according to claim 1, wherein the modification is replacement of the entire promoter regulatory region of ICP27 with a tumor-specific promoter.

10. The recombinant herpes simplex virus of claim 9, wherein the ICP27 promoter is replaced by a CXCR4 promoter.

11. The recombinant herpes simplex virus of claim 7, wherein the modification is a deletion of one copy of RL or RS.

12. The recombinant herpes simplex virus of claim 1, further comprising at least one nucleic acid encoding a non-viral protein selected from the group consisting of an immunostimulatory factor, an antibody, and a checkpoint blocking peptide, wherein the at least one nucleic acid is operably linked to a universal or tumor-specific promoter.

13. The recombinant herpes simplex virus of claim 11, wherein the non-viral protein is selected from the group consisting of IL12, IL15, IL15 receptor α subunit, CTLA-4 antagonist, PD-1 antagonist, PD-L1 antagonist and / or PD-L2 antagonist.

14. The recombinant herpes simplex virus of claim 12, wherein the universal promoter is CMV.

15. The recombinant herpes simplex virus of claim 1, further comprising a nucleic acid sequence encoding a fusion form of glycoprotein B.

16. The recombinant herpes simplex virus of claim 14, wherein the glycoprotein B is truncated by a deletion occurring after amino acid 876.

17. The recombinant herpes simplex virus of any one of claims 1 to 15, wherein the oncolytic herpes virus is HSV-1.

18. A method for inhibiting tumor cells, comprising providing a therapeutically effective amount of the recombinant herpes simplex virus according to any one of claims 1 to 17 to the tumor cells.

19. The method of claim 18, further comprising the step of providing said cells with a CTLA-4, PD-1, PD-L1 and / or PD-L2 antagonist.

20. A therapeutic composition comprising the recombinant herpes simplex virus of any one of claims 1 to 17 and a pharmaceutically acceptable carrier.

21. The therapeutic composition of claim 20, further comprising a CTLA-4, PD-1, PD-L1 and / or PD-L2 antagonist.

22. A method of treating cancer in an individual suffering from cancer, comprising the step of administering a therapeutically effective amount of the composition of claim 20.

23. The method of claim 22, wherein the cancer expresses high levels of a biomarker such as CXCR4.

24. The method of claim 22, wherein the cancer is a urological cancer.

25. The method of claim 22, further comprising the step of administering to the individual a CTLA-4, PD-1, PD-L1 and / or PD-L2 antagonist.

Citation Information

Patent Citations

  • Anti-PD-l1 antibodies and their use to enhance t-cell function

    US20100203056A1

  • Antibodies to human programmed death receptor PD-1

    US20100266617A1

  • PD-1 Antibodies

    US20110229461A1

  • Simultaneous inhibition of PD-l1 / PD-l2

    US20130017199A1

  • Anti-PD-l1 antibodies and uses thereof

    US20140341917A1